

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/34, 1/14 // C12P 19/20		A1	(11) International Publication Number: WO 99/28448 (43) International Publication Date: 10 June 1999 (10.06.99)												
<p>(21) International Application Number: PCT/DK98/00520</p> <p>(22) International Filing Date: 26 November 1998 (26.11.98)</p> <p>(30) Priority Data:</p> <table><tr><td>08/979,673</td><td>26 November 1997 (26.11.97)</td><td>US</td></tr><tr><td>1557/97</td><td>30 December 1997 (30.12.97)</td><td>DK</td></tr><tr><td>09/107,657</td><td>30 June 1998 (30.06.98)</td><td>US</td></tr><tr><td>925/98</td><td>10 July 1998 (10.07.98)</td><td>DK</td></tr></table> <p>(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).</p> <p>(72) Inventors: NIELSEN, Bjarne, Rønfeldt; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). NIELSEN, Ruby, Illum; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). LEHMBECK, Jan; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK).</p> <p>(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).</p>		08/979,673	26 November 1997 (26.11.97)	US	1557/97	30 December 1997 (30.12.97)	DK	09/107,657	30 June 1998 (30.06.98)	US	925/98	10 July 1998 (10.07.98)	DK	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	
08/979,673	26 November 1997 (26.11.97)	US													
1557/97	30 December 1997 (30.12.97)	DK													
09/107,657	30 June 1998 (30.06.98)	US													
925/98	10 July 1998 (10.07.98)	DK													
<p>(54) Title: THERMOSTABLE GLUCOAMYLASE</p> <p>(57) Abstract</p> <p>The invention relates to an isolated thermostable glucoamylase derived from <i>Talaromyces emersonii</i> suitable for starch conversion processes.</p>															

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Title: Thermostable Glucoamylase**FIELD OF THE INVENTION**

The present invention relates to a thermostable glucoamylase
5 suitable for, e.g., starch conversion, e.g., for producing
glucose from starch. The present invention also relates to the
use of said thermostable glucoamylase in various processes, in
particular in the saccharification step in starch convention
processes.

10

BACKGROUND OF THE INVENTION

Glucoamylases (1,4- α -D-glucan glucohydrolase, EC 3.2.1.3)
are enzymes which catalyze the release of D-glucose from the
non-reducing ends of starch or related oligo- and polysaccharide
15 molecules.

Glucoamylases are produced by several filamentous fungi and
yeasts, including *Aspergillus niger* and *Aspergillus awamori*.

Commercially, the glucoamylases are used to convert corn
starch which is already partially hydrolyzed by an α -amylase to
20 glucose. The glucose may further be converted by glucose
isomerase to a mixture composed almost equally of glucose and
fructose. This mixture, or the mixture further enriched with
fructose, is the commonly used high fructose corn syrup
commercialized throughout the world. This syrup is the world's
25 largest tonnage product produced by an enzymatic process. The
three enzymes involved in the conversion of starch to fructose
are among the most important industrial enzymes produced.

One of the main problems existing with regard to the
commercial use of glucoamylase in the production of high
30 fructose corn syrup is the relatively low thermal stability of
glucoamylases, such as the commercially available *Aspergillus*
niger glucoamylase (i.e., (sold as AMG by Novo Nordisk A/S). The
commercial *Aspergillus* glucoamylase is not as thermally stable
as α -amylase or glucose isomerase and it is most active and
35 stable at lower pH's than either α -amylase or glucose isomerase.
Accordingly, it must be used in a separate vessel at a lower
temperature and pH.

US patent no. 4,247,637 describes a thermostable glucoamylase having a molecular weight of about 31,000 Da derived from *Talaromyces duponti* suitable for saccharifying a liquefied starch solution to a syrup. The glucoamylase is stated
5 to retain at least about 90% of its initial glucoamylase activity when held at 70°C for 10 minutes at pH 4.5.

US patent no. 4,587,215 discloses a thermostable amyloglucosidase derived from the species *Talaromyces thermophilus* with a molecular weight of about 45,000 Da. The
10 disclosed amyloglucosidase (or glucoamylase) loses its enzymatic activity in two distinct phases, an initial period of rapid decay followed by a period of slow decay. At 70°C (pH=5.0) the half-life for the fast decay is about 18 minutes with no measurable loss of activity within an hour in the second phase
15 of decay. Bunni L et al., (1989), Enzyme Microb. Technol., Vol. 11, p. 370-375. concerns production, isolation and partial characterization of an extracellular amylolytic system composed of at least one form of α -amylase and one form of an α -glucosidase produced by *Talaromyces emersonii* CBS 814.70. Only
20 the α -amylase is isolated, purified and characterized.

BRIEF DISCLOSURE OF THE INVENTION

The present invention is based upon the finding of a novel thermostable glucoamylase suitable for use, e.g., in the
25 saccharification step in starch conversion processes.

The terms "glucoamylase" and "AMG" are used interchangeably below.

The thermal stability of the glucoamylase of the invention is measured as $T_{1/2}$ (half-life) using the method described in the
30 "Materials and Methods" section below.

The inventors of the present invention have isolated, purified and characterized a thermostable glucoamylase from a strain of *Talaromyces emersonii* now deposited with the Centraalbureau voor Schimmelcultures under the number CBS
35 793.97.

When applied to a protein, the term "isolated" indicates that the protein is found in a condition other than its native

environment. In a preferred form, the isolated protein is substantially free of other proteins, particularly other homologous proteins (i.e., "homologous impurities" (see below)).

5 It is preferred to provide the protein in a greater than 40% pure form, more preferably greater than 60% pure form. Even more preferably it is preferred to provide the protein in a highly purified form, i.e., greater than 80% pure, more preferably greater than 95% pure, and even more preferably
10 greater than 99% pure, as determined by SDS-PAGE.

The term "isolated enzyme" may alternatively be termed "purified enzyme".

The term "homologous impurities" means any impurity (e.g. another polypeptide than the polypeptide of the invention) which
15 originates from the homologous cell, from where the polypeptide of the invention is originally obtained.

The isolated glucoamylase has a very high thermal stability in comparison to prior art glucoamylases, such as the *Aspergillus niger* glucoamylase (available from Novo Nordisk A/S
20 under the trade name AMG). The $T_{1/2}$ (half-life) was determined to be about 120 minutes at 70°C (pH 4.5) as described in Example 2 below. The $T_{1/2}$ of the recombinant *T. emersonii* AMG expressed in yeast was determined to be about 110 minutes as described in Example 12.

25 Therefore, in the first aspect the present invention relates to an isolated enzyme with glucoamylase activity having a $T_{1/2}$ (half-life) of at least 100 minutes in 50 mM NaOAc, 0.2 AGU/ml, pH 4.5, at 70°C.

In the second aspect the invention relates to an enzyme with
30 glucoamylase activity comprising one or more of the partial sequences shown in SEQ ID Nos. 1-6 or the full length enzyme shown in SEQ ID NO: 7 or an enzyme with glucoamylase activity being substantially homologous thereto.

The term "partial sequence" denotes a partial
35 polypeptide sequence which is comprised in a longer polypeptide sequence, wherein said longer polypeptide sequence is having the activity of interest.

The invention also relates to the cloned DNA sequence encoding the glucoamylase of the invention.

Further, the invention also relates to a process of
5 converting starch or partially hydrolyzed starch into a syrup containing, e.g., dextrose, said process including the step of saccharifying starch hydrolyzate in the presence of a glucoamylase of the invention.

It is an object of the invention to provide a method of
10 saccharifying a liquefied starch solution, wherein an enzymatic saccharification is carried out using a glucoamylase of the invention.

Furthermore, the invention relates to the use of a glucoamylase of the invention in a starch conversion process,
15 such as a continuous starch conversion process. In an embodiment of the continuous starch conversion process it includes a continuous saccharification step.

The glucoamylase of the invention may also be used in processes for producing oligosaccharides or specialty syrups.

20 Finally, the invention relates to an isolated pure culture of the microorganism *Talaromyces emersonii* CBS 793.97 or a mutant thereof capable of producing a glucoamylase of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

25 Figure 1 shows the SDS-PAGE gel (stained with Coomassie Blue) used for determining the molecular weight (M_v) of the purified *Talaromyces emersonii* CBS 793.97 glucoamylase of the present invention.

- 1: Standard marker,
30 2: Q Sepharose pool (1. run)
3: S Sepharose pool;

Figure 2 shows the pH activity profile of *Talaromyces emersonii* and *Aspergillus niger* glucoamylase (AMG) in 0.5% maltose at 60°C;

35 Figure 3 shows the temperature activity profile of the *Talaromyces emersonii* CBS 793.97 glucoamylase vs. *Aspergillus niger* glucoamylase (AMG);

Figure 4 shows the curve for determining $T_{1/2}$ (half-life) in

50 mM NaOAc, 0.2 AGU/ml, pH 4.5, at 70°C of *Talaromyces emersonii* CBS 793.97 glucoamylase vs. *Aspergillus niger* glucoamylase (AMG);

Figure 5 shows the sequence of the *Talaromyces emersonii* AMG locus. The predicted amino acid sequence is shown below the nucleotide sequence. The four introns are shown in lower case letters. Consensus introns sequences are underlined. Putative signal and pro-peptides are double underlined and dotted underline, respectively;

Figure 6 shows an alignment/comparison of the amino acid sequences of the *A.niger* AMG (An_amg-1.pro), *A.oryzae* AMG (Ao_AMG.pro), and *Talaromyces emersonii* AMG (Tal-AMG.pro). Identical amino acid residues are indicated by a *. Signal and pro peptides are underlined by a single and a double lined, respectively;

Figure 7 shows the *Aspergillus* expression cassette pCaHj483 used in Example 5;

Figure 8 shows the *Aspergillus* expression plasmid, pJal518, for the *Talaromyces emersonii* AMG gene;

Figure 9 shows the construction of *A.niger* disruption plasmid;

Figure 10 shows the SDS page gel of two transformants, JaL228#5.77 and HowB112#8.10, expressing the *Talaromyces emersonii* glucoamylase of the invention. JaL228 and HowB112 are the untransformed parent strains. MW: Promega's Protein Molecular;

Figure 11 shows the thermal stability of the *T. emersonii* AMG produced the strain *A. niger* HowB112 determined in 50mM NaOAc, pH 4.5, 70°C, 0.2 AGU/ml (T1/2 determined to 20 minutes);

Figure 12 compares the thermal stability at 68°C of the fermentation broth of *T. emersonii* AMG expressed in yeast produced in yeast and the *A. niger* AMG;

Figure 13 shows the result of the test for determining the thermostability of recombinant *Talaromyces emersonii* AMG produced in yeast at 70°C, pH 4.5, 0.2 AGU/ml. T1/2 was determined to about 110°C.

DETAILED DISCLOSURE OF THE INVENTION

The present invention is based upon the finding of a novel thermostable glucoamylase suitable for use in, e.g., the saccharification step in a starch conversion process.

5 The inventors of the present invention have isolated, purified and characterized a glucoamylase from a strain of *Talaromyces emersonii* CBS 793.97. The glucoamylase turned out to have a very high thermal stability in comparison to prior art glucoamylases.

10 Accordingly, in a first aspect the present invention relates to an isolated enzyme with glucoamylase activity having a $T_{1/2}$ (half-life) of at least 100 minutes, such as between 100 and 140 minutes, in 50 mM NaOAc, 0.2 AGU/ml, pH 4.5, at 70°C.

$T_{1/2}$ (half-life) of the isolated *Talaromyces emersonii* CBS
15 793.97 glucoamylase was determined to be about 120 minutes at 70°C as described in Example 2 below and to be about 110°C for the *T. emersonii* produced in yeast as described in Example 12.

The molecular weight of the isolated glucoamylase was found to be about 70 kDa determined by SDS-PAGE. Further, the pI of
20 said enzyme was determined to be below 3.5 using isoelectrical focusing.

The isoelectric point, pI, is defined as the pH value where the enzyme molecule complex (with optionally attached metal or other ions) is neutral, i.e., the sum of electrostatic charges
25 (net electrostatic charge, NEC) on the complex is equal to zero. In this sum of course consideration of the positive or negative nature of the electrostatic charge must be taken into account.

It is expected that substantially homologous enzymes having the same advantageous properties are obtainable from other
30 micro-organisms, especially fungal organisms such as filamentous fungi, in particular from another strain of *Talaromyces*, especially another strains of *Talaromyces emersonii*.

The deposited micro-organism

35 An isolate of the filamentous fungus strain, from which the glucoamylase of the invention has been isolated, has been deposited with the Centraalbureau voor Schimmelcultures, P.O. Box 273, 3740 AG Baarn, the Netherlands, for the purposes of

patent procedure on the date indicated below. CBS being an international depository under the Budapest Treaty affords permanence of the deposit in accordance with rule 9 of said treaty.

5 Deposit date : June 2, 1997

Depositor's ref.: NN049253

CBS designation : CBS 793.97

The isolate of the filamentous fungus *Talaromyces emersonii* CBS No. 793.97 has been deposited under conditions that assure
10 that access to the isolated fungus will be available during the pendency of this patent application to one determined by the commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R. § 1.14 and 35 U.S.C § 122. The deposit represents a substantially pure culture of the isolated fungus.
15 The deposit is available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights
20 granted by governmental action.

Talaromyces emersonii glucoamylase amino acid sequence

The inventors have sequenced the thermostable glucoamylase derived from *Talaromyces emersonii* CBS 793.97 as will be
25 described further in the Example 3 below. According to the invention the *Talaromyces* AMG may have a Asp145Asn (or D145N) substitution (using SEQ ID NO: 7 numbering).

Therefore, the invention also relates to an isolated enzyme with glucoamylase activity comprising one or more of the partial
30 sequences shown in SEQ ID NOS: 1-6 or the full length sequence shown in SEQ ID NO: 7 or an enzyme with glucoamylase activity being substantially homologous thereto. SEQ ID NO: 34 shows the full length sequence including the signal and pre propeptide from amino acid no. 1 to 27.

35

Homology of the protein sequence

The homology between two glucoamylases is determined as the degree of identity between the two protein sequences

indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art such as gap provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, p. 443-453). Using gap with the following settings for polypeptide sequence comparison: gap creation penalty of 3.0 and gap extension penalty of 0.1.

According to the invention a "substantially homologous" amino acid sequence exhibits a degree of identity preferably of at least 80%, at least 90%, more preferably at least 95%, more preferably at least 97%, and most preferably at least 99% with the partial amino acid sequences shown in SEQ ID NO: 1-6 or SEQ ID NO: 7.

The Cloned *Talaromyces emersonii* DNA sequence

The invention also relates to a cloned DNA sequence encoding an enzyme exhibiting glucoamylase activity of the invention, which DNA sequence comprises:

- (a) the glucoamylase encoding part of the DNA sequence shown in SEQ ID NO: 33;
- (b) the DNA sequence shown in positions 649-2724 in SEQ ID NO:33 or its complementary strand;
- (c) an analogue of the DNA sequence defined in (a) or (b) which is at least 80% homologous with said DNA sequence;
- (d) a DNA sequence which hybridizes with a double-stranded DNA probe comprising the sequence shown in 649-2724 in SEQ ID NO: 33 at low stringency;
- (e) a DNA sequence which, because of the degeneracy of the genetic code, does not hybridize with the sequences of (b) or (f), but which codes for a polypeptide having exactly the same amino acid sequence as the polypeptide encoded by any of these DNA sequences; or
- (g) a DNA sequence which is a fragment of the DNA sequences specified in (a), (b), (c), (d), or (e).

The mature part of the AMG of the invention is encoded by

the DNA sequence in position 728-2724 of SEQ ID NO: 33. When expressing the AMG of the invention in yeast, e.g., *Saccharomyces cerevisiae* YNG318, the introns need to be cut out as described in Example 7.

5

Homology of DNA sequences

The DNA sequence homology referred to above is determined as the degree of identity between two sequences indicating a derivation of the first sequence from the second. The homology
10 may suitably be determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, C.D.,
15 (1970), Journal of Molecular Biology, 48, 443-453). Using GAP with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous DNA sequences referred to above exhibits a degree of identity preferably of at least 80%, more
20 preferably at least 90%, more preferably at least 95%, more preferably at least 97% with the AMG encoding part of the DNA sequence shown in SEQ ID NO: 33 or the glucoamylase encoding part with or without introns.

25 Hybridization:

The hybridization conditions referred to above to define an analogous DNA sequence as defined in d) above which hybridizes
to a double-stranded DNA probe comprising the sequence shown in
30 positions 649-2748 in SEQ ID NO: 33 (i.e., the AMG encoding part), under at least low stringency conditions, but preferably at medium or high stringency conditions are as described in detail below.

Suitable experimental conditions for determining
35 hybridization at low, medium, or high stringency between a nucleotide probe and a homologous DNA or RNA sequence involves presoaking of the filter containing the DNA fragments or RNA to hybridize in 5 x SSC (Sodium chloride/Sodium citrate, Sambrook

et al. 1989) for 10 min, and prehybridization of the filter in a solution of 5 x SSC, 5 x Denhardt's solution (Sambrook et al. 1989), 0.5 % SDS and 100 µg/ml of denatured sonicated salmon sperm DNA (Sambrook et al. 1989), followed by hybridization in
5 the same solution containing a concentration of 10ng/ml of a random-primed (Feinberg, A. P. and Vogelstein, B. (1983) Anal. Biochem. 132:6-13), ³²P-dCTP-labeled (specific activity > 1 x 10⁹ cpm/µg) probe for 12 hours at about 45°C. The filter is then washed twice for 30 minutes in 2 x SSC, 0.5 % SDS at about 55°C
10 (low stringency), more preferably at about 60°C (medium stringency), still more preferably at about 65°C (medium/high stringency), even more preferably at about 70°C (high stringency), and even more preferably at about 75°C (very high stringency).

15 Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using a x-ray film.

Starch conversion

The present invention provides a method of using the
20 thermostable glucoamylase of the invention for producing glucose and the like from starch. Generally, the method includes the steps of partially hydrolyzing precursor starch in the presence of α-amylase and then further hydrolyzing the release of D-glucose from the non-reducing ends of the starch or related
25 oligo- and polysaccharide molecules in the presence of glucoamylase by cleaving α-(1→4) and α-(1→6) glucosidic bonds.

The partial hydrolysis of the precursor starch utilizing α-amylase provides an initial breakdown of the starch molecules by hydrolyzing internal α-(1→4)-linkages. In commercial
30 applications, the initial hydrolysis using α-amylase is run at a temperature of approximately 105°C. A very high starch concentration is processed, usually 30% to 40% solids. The initial hydrolysis is usually carried out for five minutes at this elevated temperature. The partially hydrolyzed starch can
35 then be transferred to a second tank and incubated for approximately one hour at a temperature of 85° to 90°C to derive a dextrose equivalent (D.E.) of 10 to 15.

The step of further hydrolyzing the release of D-glucose from the non-reducing ends of the starch or related oligo- and polysaccharides molecules in the presence of glucoamylase is normally carried out in a separate tank at a reduced temperature
5 between 30° and 60°C. Preferably the temperature of the substrate liquid is dropped to between 55° and 60°C. The pH of the solution is dropped from 6 to 6.5 to a range between 3 and 5.5. Preferably, the pH of the solution is 4 to 4.5. The glucoamylase is added to the solution and the reaction is
10 carried out for 24-72 hours, preferably 36-48 hours.

By using a thermostable glucoamylase of the invention saccharification processes may be carried out at a higher temperature than traditional batch saccharification processes. According to the invention saccharification may be carried out
15 at temperatures in the range from above 60-80°C, preferably 63-75°C. This applies both for traditional batch processes (described above) and for continuous saccharification processes.

Actually, continuous saccharification processes including one or more membrane separation steps, i.e., filtration steps,
20 must be carried out at temperatures of above 60°C to be able to maintain a reasonably high flux over the membrane. Therefore, a thermostable glucoamylase of the invention provides the possibility of carrying out large scale continuous saccharification processes at a fair price within and period of
25 time acceptable for industrial saccharification processes. According to the invention the saccharification time may even be shortened.

The activity of a glucoamylase of the invention is generally substantially higher at temperatures between 60°C-80°C
30 than at the traditionally used temperature between 30-60°C. Therefore, by increasing the temperature at which the glucoamylase operates the saccharification process may be carried out within a shorter period of time or the process may be carried out using lower enzyme dosage.

35 As the thermal stability of the glucoamylase of the invention is very high in comparison to, e.g., the commercially available *Aspergillus niger* glucoamylase (i.e., AMG) a less

amount of glucoamylase needs to be added to replace the glucoamylase being inactivated during the saccharification process. More glucoamylase is maintained active during saccharification process according to the present invention.
5 Furthermore, the risk of microbial contamination is also reduced when carrying the saccharification process at temperature above 63°C.

By using a glucoamylase with increased specific activity (measured as activity towards maltose), a lower enzyme dosage
10 may be required in the saccharification process.

Examples of saccharification processes, wherein the glucoamylase of the invention may advantageously be used include the processes described in JP 3-224493; JP 1-191693; JP 62-272987; and EP 452,238.

15 In a further aspect the invention relates to a method of saccharifying a liquefied starch solution, which method comprises an enzymatic saccharification step using a glucoamylase of the invention.

The glucoamylase of the invention may be used in the present
20 inventive process in combination with an enzyme that hydrolyzes only α -(1 \rightarrow 6)-glucosidic bonds in molecules with at least four glucosyl residues. Preferably, the glucoamylase of the invention is used in combination with pullulanase or isoamylase. The use of isoamylase and pullulanase for debranching, the molecular
25 properties of the enzymes, and the potential use of the enzymes with glucoamylase is set forth in G.M.A. van Beynum et al., Starch Conversion Technology, Marcel Dekker, New York, 1985, 101-142.

In a further aspect the invention relates to the use of a
30 glucoamylase of the invention in a starch conversion process.

Further, the glucoamylase of the invention may be used in a continuous starch conversion process including a continuous saccharification step.

The glucoamylase of the invention may also be used in
35 immobilised form. This is suitable and often used for producing speciality syrups, such as maltose syrups, and further for the raffinate stream of oligosaccharides in connection with the

production of fructose syrups.

The glucoamylase of the invention may also be used in a process for producing ethanol for fuel or beverage or may be used in a fermentation process for producing organic compounds, such as citric acid, ascorbic acid, lysine, glutamic acid.

MATERIALS AND METHODS

Material

Enzymes:

10 Glucoamylase derived from the deposited filamentous fungus *Talaromyces emersonii* CBS No. 793.97 has been deposited with the Centraalbureau voor Schimmelcultures, P.O. Box 273, 3740 AG Baarn, the Netherlands, for the purposes of patent procedure on the date indicated below. CBS being an international depository
15 under the Budapest Treaty affords permanence of the deposit in accordance with rule 9 of said treaty.

Deposit date : June 2, 1997

Depositor's ref.: NN049253

CBS designation : CBS 793.97

20

Glucoamylase G1 derived from *Aspergillus niger* disclosed in Boel et al. (1984), EMBO J. 3 (5), 1097-1102, available from Novo Nordisk and shown in SEQ ID NO: 9.

25 **Strains:**

JaL228; Construction of this strain is described in WO98/12300
SMO110; Construction of this strain is described in Example 6
Yeast Strain: *Saccharomyces cerevisiae* YNG318: MATa leu2-D2
ura3-52 his4-539 pep4-D1[cir+].

30

Genes:

A. niger G1 glucoamylase gene is shown in SEQ ID NO: 8

T. emersonii glucoamylase gene with introns is shown in fig. 5 and SEQ ID NO: 33. The introns are shown in Fig. 5.

35

Plasmids:

pJS0026 (*S. cerevisiae* expression plasmid) (J.S. Okkels, (1996)) "A URA3-promoter deletion in a pYES vector increases the expression

- level of a fungal lipase in *Saccharomyces cerevisiae*. Recombinant DNA Biotechnology III: The Integration of Biological and Engineering Sciences, vol. 782 of the Annals of the New York Academy of Sciences) More specifically, the expression plasmid
- 5 pJS026, is derived from pYES 2.0 by replacing the inducible GAL1-promoter of pYES 2.0 with the constitutively expressed TPI (triose phosphate isomerase)-promoter from *Saccharomyces cerevisiae* (Albert and Karwasaki, (1982), J. Mol. Appl Genet., 1, 419-434), and deleting a part of the URA3 promoter.
- 10 pJaL497; Construction of this plasmid is described in Example 5
pJaL507; Construction of this plasmid is described in Example 5
pJaL510; Construction of this plasmid is described in Example 5
pJaL511; Construction of this plasmid is described in Example 5
pJaL518; Construction of this plasmid is described in Example 6
- 15 pCaHj483; Construction of this plasmid is described in Example 6
- pJRoy10; Construction of this plasmid is described in Example 6
pJRoy17; Construction of this plasmid is described in Example 6
pSM0127; Construction of this plasmid is described in Example 6
- 20 pCRTMII; Available from Invitrogen Corporation, San Diego, CA, USA.

Equipment:

Automatic DNA Sequencer (Applied Biosystems Model 377)

25

Media:

SC-ura medium:

	Yeast Nitrogen w/o ami	7.5 g
	Bernsteinsäure (Ravsyre)	11.3 g
30	NaOH	6.8 g
	Casaminoacid w/o vit	5.6 g
	Tryptophan	0.1 g
	Dest. water ad	1000 ml

Autoclaved for 20 minutes at 121°C.

- 35 From a sterile stock solution of 5% Threonin 4 ml is added to a volume of 900 ml together with 100 ml of a sterile 20% glucose.

YPD medium:

Yeast extract 10 g
Peptone 20 g
Dest. water ad 1000 ml

- 5 Autoclaved for 20 minutes at 121°C
100 ml of a sterile 20% glucose is added to 900 ml.

Methods:

Determination of AGU activity

- 10 One Novo Amyloglucosidase Unit (AGU) is defined as the amount of enzyme which hydrolyzes 1 micromole maltose per minute under the following standard conditions:

Substrate. maltose

Temperature. 25°C

- 15 pH. 4.3 (acetate buffer)

Reaction time. . . . 30 minutes

A detailed description of the analytical method (AF22) is available on request.

20 Determination of PUN activity

PUN is defined as the amount of enzyme which hydrolyzes pullulan (0.2 % pullulan, 40°C, pH 5.0), liberating reducing carbohydrate with a reducing power equivalent to 1 micro-mol glucose pr. minute.

25

Determination of AFAU activity

The activity is determined in AFAU calculated as the reduction in starch concentration at pH 2.5, 40°C, 0.17 g/l starch and determined by an iodine-starch reaction.

30

Thermal Stability I (T½ (half-life) determination of AMG

- The thermal stability of glucoamylase (determined as T½ (half-life)) is tested using the following method: 950 microliter 50 mM sodium acetate buffer (pH 4.5) (NaOAc) is
35 incubated for 5 minutes at 70°C. 50 microliter enzyme in buffer (4 AGU/ml) is added. 2 x 40 microliter samples are taken at fixed periods between 0 and 360 minutes and chilled on ice.

After chilling the samples the residual enzyme activity is measured using the AGU determination assay (described above).

The activity (AGU/ml) measured before incubation (0 minutes) is used as reference (100%). $T_{1/2}$ is the period of time until which the percent relative activity is decreased to 50%.

Determination of thermal stability II

1600 microliter of a supernatant and 400 microliter of 0.5M NaAC pH 4.5 is mixed.

10 7 eppendorph tubes each containing 250 microliter of the mixture are incubated in a Perkin Elmer thermocycler at 68°C or 70°C for 0, 5, 10, 20, 30, 45 and 60 minutes.

100 microliter from each mixture is mixed with 100 microliter of 5 mM CNPG3 (2-chloro-4-Nitrophenyl-Alpha-Maltotrioxide from genzyme) in microtiterwells. After incubation for 30 minutes at 37°C the absorbance is measured at 405 nm.

Determination of Specific Activity of a glucoamylase

20 750 microL substrate is incubated 5 minutes at selected temperatures, such as 37°C, 60°C or 70°C.

50 microL enzyme diluted in sodium acetate is added, and the activity was determined using the AGU standard method described above. The kinetic parameters: K_{cat} and K_m are measured at 45°C by adding 50 microL enzyme diluted in sodium acetate to preheated 750 microL substrate. Aliquots of 100 microL are removed after 0, 3, 6, 9 and 12 minutes and transferred to 100 microL 0.4M Sodium hydroxide to stop the reaction. A blank is included.

30 20 microL is transferred to a Micro titre plates and 200 microL GOD-Perid solution is added. Absorbance is measured at 650 nm after 30 minutes incubation at room temperature. Glucose is used as standard, and the specific activity is calculated as k_{cat} (sec.⁻¹)

35

Transformation of *Aspergillus oryzae* (general procedure)

100 ml of YPD (Sherman et al., (1981), Methods in Yeast

Genetics, Cold Spring Harbor Laboratory) is inoculated with spores of *A. oryzae* and incubated with shaking for about 24 hours. The mycelium is harvested by filtration through miracloth and washed with 200 ml of 0.6 M MgSO_4 . The mycelium
5 is suspended in 15 ml of 1.2 M MgSO_4 , 10 mM NaH_2PO_4 , pH 5.8. The suspension is cooled on ice and 1 ml of buffer containing 120 mg of Novozym™ 234 is added. After 5 min., 1 ml of 12 mg/ml BSA (Sigma type H25) is added and incubation with gentle agitation continued for 1.5-2.5 hours at 37C until a large
10 number of protoplasts is visible in a sample inspected under the microscope.

The suspension is filtered through miracloth, the filtrate transferred to a sterile tube and overlaid with 5 ml of 0.6 M sorbitol, 100 mM Tris-HCl, pH 7.0. Centrifugation is performed
15 for 15 min. at 1000 g and the protoplasts are collected from the top of the MgSO_4 cushion. 2 volumes of STC (1.2 M sorbitol, 10 mM Tris-HCl, pH 7.5, 10 mM CaCl_2) are added to the protoplast suspension and the mixture is centrifuged for 5 min. at 1000 g. The protoplast pellet is resuspended in 3 ml of
20 STC and repelleted. This is repeated. Finally, the protoplasts are resuspended in 0.2-1 ml of STC.

100 μl of protoplast suspension are mixed with 5-25 μg of p3SR2 (an *A. nidulans* amdS gene carrying plasmid described in Hynes et al., Mol. and Cel. Biol., Vol. 3, No. 8, 1430-1439,
25 Aug. 1983) in 10 μl of STC. The mixture is left at room temperature for 25 min. 0.2 ml of 60% PEG 4000 (BDH 29576), 10 mM CaCl_2 and 10 mM Tris-HCl, pH 7.5 is added and carefully mixed (twice) and finally 0.85 ml of the same solution are added and carefully mixed. The mixture is left at room
30 temperature for 25 min., spun at 2.500 g for 15 min. and the pellet is resuspended in 2 ml of 1.2M sorbitol. After one more sedimentation the protoplasts are spread on minimal plates (Cove, (1966), Biochem. Biophys. Acta 113, 51-56) containing 1.0 M sucrose, pH 7.0, 10 mM acetamide as nitrogen source and
35 20 mM CsCl to inhibit background growth. After incubation for 4-7 days at 37C spores are picked, suspended in sterile water and spread for single colonies. This procedure is repeated and

spores of a single colony after the second re-isolation are stored as a defined transformant.

Fed batch fermentation

5 Fed batch fermentation is performed in a medium comprising maltodextrin as a carbon source, urea as a nitrogen source and yeast extract. The fed batch fermentation is performed by inoculating a shake flask culture of fungal host cells in question into a medium comprising 3.5% of the carbon source and
10 0.5% of the nitrogen source. After 24 hours of cultivation at pH 5.0 and 34°C the continuous supply of additional carbon and nitrogen sources are initiated. The carbon source is kept as the limiting factor and it is secured that oxygen is present in excess. The fed batch cultivation is continued for 4 days, after
15 which the enzymes can be recovered by centrifugation, ultrafiltration, clear filtration and germ filtration. Further purification may be done by anionexchange chromatographic methods known in the art.

20 Transformation of *Saccharomyces cerevisiae* YNG318

The DNA fragments and the opened vectors are mixed and transformed into the yeast *Saccharomyces cerevisiae* YNG318 by standard methods.

25 **EXAMPLES**

Example 1

Purification

3500 ml *T. emersonii* culture broth from wild-type
30 fermentation with 0.05 AGU/ml was centrifuged at 9000 rpm followed by vacuum filtration through filter paper and finally a blank filtration. The following procedure was then used to purify the enzyme:

Phenyl Sepharose (250 ml): 1,3 M AMS/10 mM Tris/2 mM CaCl₂, pH
35 7; elution with 10 mM Tris/2 mM CaCl₂, pH 7.

Dialysis: 20 mM NaAc, 2mM CaCl₂, pH 5.

Q Sepharose (100 ml): 20 mM NaAc, 2mM CaCl₂, pH 5; elution with a linear gradient from 0-0.4 M NaCl over 10 column volumes.

Dialysis: 20 mM NaAc, 2 mM CaCl₂, pH 5.

Colour removal: 0.5% coal in 10 minutes.

Q Sepharose (20 ml): 20 mM NaAc, 2mM CaCl₂, pH 4.5; elution with a linear gradient from 0-0.4 M NaCl over 10 column volumes.

Dialysis: 20 mM NaAc, 2mM CaCl₂, pH 5.

S Sepharose (1 ml): 5 mM citric acid, pH 2.9; elution with a linear gradient from 0-0.3 M NaCl over 10 column volume.

A purity of the enzyme of more than 90% was obtained after the S Sepharose step.

Example 2

Characterisation of the *Talaromyces emersonii* glucoamylase

The purified *Talaromyces emersonii* CBS 793.97 glucoamylase was used for characterisation.

Molecular weight (M_w)

The molecular weight was determined by SDS-PAGE to around 70 kDa as shown in Figure 1.

pI

The pI was determined to lie below 3.5 by isoelectrical focusing (Amploline PAG, pH 3.5-9.5 from Pharmacia).

pH profile

The pH-activity dependency of the *Talaromyces emersonii* glucoamylase was determined and compared with profile of *Aspergillus niger* glucoamylase.

The pH activity profile was determined using 0.5% maltose as substrate in 0.1 M sodium acetate at 60°C. The pH was measured in duple samples comprising 0.1-1 AGU/ml. The result of the test is shown in Figure 2.

Temperature profile

The temperature-activity dependency of the *Talaromyces emersonii* glucoamylase of the invention was determined and compared with the profile of *Aspergillus niger* glucoamylase. 200 µl 0.5% maltose, pH 4.3 was incubated at 37, 50, 60, 70,

75, 80 and 90°C and the reaction was started by adding 10 µl enzyme (0.25 AGU/ml); reaction time was 10 minutes. The result of the test is shown in Figure 3.

5 Temperature stability - T½ (half-life)

The thermal stability of the *Talaromyces emersonii* glucoamylase was determined and compared with the thermal stability of *Aspergillus niger* glucoamylase.

The method used is described above in the "Material and
10 Methods" section as "Thermal Stability I (T½ (half-life) determination of AMG".

The T½ of the *Talaromyces emersonii* glucoamylase was determined to about 120 minutes at 70°C. The T½ of the *Aspergillus niger* glucoamylase was determined to 7 minutes
15 under the same conditions (See Figure 4).

Specific activity

The extension coefficient was determined to: $\epsilon = 2.44$ ml/mg*cm on basis of absorbency at 280 nm and protein
20 concentration. The specific activity towards maltose at 37°C was then calculated to 7.3 AGU/mg. Purity of the sample was approximately 90% and a corrected specific activity is therefore 8.0 AGU/mg. Following specific activities were measured:

AMG	Specific activity (AGU/mg)		
	37°C	60°C	70°C
<i>T. emersonii</i> *	8.0	21	27
<i>A. niger</i>	2.0	6.6	8.0

25

*) Estimated for pure enzyme.

EXAMPLE 3

Sequencing of the N-terminal of *T. emersonii* glucoamylase

30 The N-terminal amino acid sequence of *T. emersonii* glucoamylase was determined following SDS-PAGE and electroblotting onto a PVDF-membrane. Peptides were derived from

reduced and S-carboxymethylated glucoamylase by cleaving with a lysyl-specific protease. The resulting peptides were fractionated and re-purified using RP-HPLC before subjected to N-terminal sequence determination.

5

N-terminal sequence (SEO ID NO: 1):

Ala Asn Gly Ser Leu Asp Ser Phe Leu Ala Thr Glu Xaa Pro Ile Ala
Leu Gln Gly Val Leu Asn Asn Ile Gly

10 Peptide 1 (SEO ID NO: 2):

Val Gln Thr Ile Ser Asn Pro Ser Gly Asp Leu Ser Thr Gly Gly Leu
Gly Glu Pro Lys

Peptide 2 (SEO ID NO: 3):

15 Xaa Asn Val Asn Glu Thr Ala Phe Thr Gly Pro Xaa Gly Arg Pro Gln
Arg Asp Gly Pro Ala Leu

Peptide 3 (SEO ID NO: 4):

20 Asp Val Asn Ser Ile Leu Gly Ser Ile His Thr Phe Asp Pro Ala Gly
Gly Cys Asp Asp Ser Thr Phe Gln Pro Cys Ser Ala Arg Ala Leu Ala
Asn His Lys

Peptide 4 (SEO ID NO: 5):

25 Thr Xaa Ala Ala Ala Glu Gln Leu Tyr Asp Ala Ile Tyr Gln Trp Lys

Peptide 5 (SEO ID NO: 6):

Ala Gln Thr Asp Gly Thr Ile Val Trp Glu Asp Asp Pro Asn Arg Ser
Tyr Thr Val Pro Ala Tyr Cys Gly Gln Thr Thr Ala Ile Leu Asp Asp
Ser Trp Gln
30 Xaa denoted a residue that could not be assigned.

EXAMPLE 4

The full length *T. emersonii* glucoamylase

35 The full length *T. emersonii* glucoamylase amino acid
sequence shown in SEQ ID NO: 7 was identified using standard
methods.

Example 5

Cloning and sequencing of the *Talaromyces emersonii* glucoamylase gene

PCR cloning parts of the *Talaromyces emersonii* AMG gene

For cloning of the *Talaromyces emersonii* AMG gene
5 degenerated primers shown in table 1 was designed for PCR
amplification of part of the AMG gene.

Table 1

Primer no:	Sequence	Comments
	V L N N I G	N-Terminal
102434 (SEQ ID NO:10)		
102435 (SEQ ID NO:11)	5'-GTNTTRAAYAAAYATHGG 5'-GTNCTNAAYAAAYATHGG	5' primers
	D L W E E V	Active site
117360 (SEQ ID NO:12)		consensus 3'
117361 (SEQ ID NO:13)	CTRGANACCCTYCTYCA-5' CTRAAYACCCTYCTYCA-5'	primers
	W E D D P N	C-Terminal
127420 (SEQ ID NO:14)		3' primers
	ACCCTYCTRCTRGGNTT-5'	

Genomic DNA from *Talaromyces emersonii* was prepared from
10 protoplasts made by standard procedures [cf.e.g., Christensen et
al. Biotechnology 1989 6 1419-1422] and was used as template in
the PCR reaction. Amplification reaction were performed in 100 µl
volumes containing 2.5 units Taq-polymerase, 100 ng of *A.oryzae*
genomic DNA, 50 mM KCl, 10 mM Tris-HCl pH 8.0, 1.5 mM MgCl₂, 250
15 nM of each dNTP, and 100pM of each of the following primers sets:
102434/117360, 102434/117361, 102435/117360, 102434/117361,
102434/127420, and 102434/127420.

Amplification was carried out in a Perkin-Elmer Cetus DNA
Termal 480, and consisted of one cycle of 3 minutes at 94°C,
20 followed by 30 cycles of 1 minutes at 94°C, 30 seconds at 40°C,
and 1 minutes at 72°C. Only the PCR reaction 102434/117360 gave
products. Four bands was detected with the following sizes
1400, 800, 650, and 525bp. All four bands were purified and
cloned into the vector pCR®2.1 (Invitrogen®). Sequencing of a

few clone from each band and sequence comparisons to the *A.niger* AMG, revealed that a clone from the 650 bp band encodes for the N-terminal part of the *Talaromyces emersonii* AMG. This clone was designated pJaL497.

5 To obtained more of the gene a specific primer (123036: 5'-GTGAGCCCAAGTTCAATGTG- 3' (SEQ ID NO:15) was made out from the sequence of clone pJaL497. The primer set 123036/127420 was used for PCR on *Talaromyces* genomic DNA and a single fragment on 1500 bp was obtained. The PCR fragment was clone into the
10 vector pCR[®]2.1 and sequenced. By sequencing the clone was confirmed to encoded the C-terminal part of the *Talaromyces emersonii* AMG. The clone was designated pJaL507.

15 Genomic restriction mapping and cloning of a genomic clone(s)

Taken together the two clones pJaL497 and pJaL507 covered about 95% of the AMG gene. In order to clone the missing part of the AMG gene a genomic restriction map was constructed by using the two PCR fragment as probes to a Southern blot of
20 *Talaromyces emersonii* genomic DNA digested with single or a combination of a number of restriction enzymes. This shows that the *Talaromyces emersonii* AMG gene is located on two EcoRI fragment on about 5.6 kb and 6.3 kb, respectively.

Talaromyces emersonii genomic DNA was digested with EcoRI
25 and fragments with the size between 4-7 kb was purified and used for construction of a partially genome library in Lambda ZAP II as described by the manufactory instruction(Stratagene). The library was first screened using the 0.7 kb EcoRI fragment from pJaL497 (encoding the N-terminal half of the AMG gene) as
30 probe to get the start of the AMG gene. One clone was obtained and designated pJaL511. In a second screening of the library using a 0.75 kb EcoRV fragment from pJaL507 (encoding the C-terminal half of the AMG gene) as probe in order to get the C-terminal end of the AMG gene. One clone was obtained and
35 designated pJaL510.

Sequence analysis of the *Talaromyces emersonii* AMG gene

The AMG gene sequence was obtained by sequencing on the plasmids: pJaL497, pJaL507, pJaL510, and pJaL511 and on subclones hereof with the standard reverse and forward primers for pUC. Remaining gaps were closed by using specific
5 oligonucleotide as primers.

Potential introns were found by comparing the sequence with consensus sequences for introns in *Aspergillus* and with the *A.niger* AMG sequence. The *Talaromyces emersonii* AMG nucleotide sequence has an open reading frame encoding a protein on 618
10 amino acid, interrupted by four introns of 57 bp, 55 bp, 48 bp, and 59 bp, respectively. The nucleotide sequence (with introns) and deduced amino acid sequence is shown in Fig. 5. The DNA sequence (with introns) is also shown in SEQ ID NO: 33 and the *Talaromyces emersonii* AMG sequence (with signal sequence from 1
15 to 27) is shown in SEQ ID NO: 34. Comparison of the deduced amino acid sequence with the *A.oryzae* AMG and *A.niger* AMG shows an identity of 60.1 % and 60.5 %, respectively. Alignment of the amino acid sequences shown in Fig. 6 shows that the *Talaromyces* AMG has a very short hinge between the catalytic
20 domain and the starch binding domain, which is also seen for the *A.oryzae* AMG.

Example 6

Construction of the *Aspergillus* vector pCaHj483

25 Construction of pCaHj483 is depicted in Fig. 7. Said plasmid is build from the following fragments:

- a) The vector pToC65 (WO 91/17243) cut with *EcoRI* and *XbaI*.
- b) A 2.7 kb *XbaI* fragment from *A. nidulans* carrying the *amdS* gene (C. M. Corrick et al., Gene 53, (1987), 63-71). The
30 *amdS* gene is used as a selective marker in fungal transformations. The *amdS* gene has been modified so that the *BamHI* site normally present in the gene is destroyed. This has been done by introducing a silent point mutation using the primer:

35 5'-AGAAATCGGGTATCCTTTCAG- 3' (SEQ ID NO:16)

- c) A 0.6 kb *EcoRI/BamHI* fragment carrying the *A. niger* NA2 promoter fused to a 60bp DNA fragment of the sequence encoding the 5' untranslated end of the mRNA of the *A. nidulans tpi*

gene. The NA2 promoter was isolated from the plasmid pNA2 (described in WO 89/01969) and fused to the 60 bp *tpi* sequence by PCR. The primer encoding the 60 bp *tpi* sequence had the following sequence:

5 5'-GCTCCTCATGGTGGATCCCCAGTTGTGTATATAGAGGATTGAGGAAGGAAGAGAAGTGT
GGATAGAGGTAAATTGAGTTGGAACTCCAAGCATGGCATCCTTGC - 3' (SEQ ID
NO:17)

d) A 675 bp *XbaI* fragment carrying the *A. niger* glucoamylase transcription terminator. The fragment was
10 isolated from the plasmid pICAMG/Term (described in EP 0238 023).

The *BamHI* site of fragment c was connected to the *XbaI* site in front of the transcription terminator on fragment d via the pIC19R linker (*BamHI* to *XbaI*)

15

Construction of a AMG expression plasmid, pJaL518

The coding region of the *Talaromyces emersonii* AMG gene was amplified by PCR, using the following two oligonucleotides primers: 139746:

20 5'-GACAGATCTCCACCATGGCGTCCCTCGTTG 3' (SEQ ID NO:18); and
primer 139747:

5'-GACCTCGAGTCACTGCCAACTATCGTC 3' (SEQ ID NO:19). The
underlined regions indicate sequences present in the
Talaromyces emersonii AMG gene. To facilitate cloning a
25 restriction enzyme site was inserted into the 5' end of each
primer; primer 139746 contains a *BglII* site and primer 139747
contains a *XhoI* site.

Talaromyces emersonii genomic DNA was used as template in the PCR reaction. The reaction was performed in a volume of 100 μ l
30 containing 2.5 units Taq polymerase, 100 ng of pSO2, 250 nM of
each dNTP, and 10 pmol of each of the two primers described
above in a reaction buffer of 50 mM KCl, 10 mM Tris-HCl pH 8.0,
1.5 mM MgCl₂.

Amplification was carried out in a Perkin-Elmer Cetus DNA
35 Thermal 480, and consisted of one cycle of 3 minutes at 94°C,
followed by 25 cycles of 1 minute at 94°C, 30 seconds at 55°C,
and 1 minute at 72°C. The PCR reaction produced a single DNA
fragment of 2099 bp in length. This fragment was digested with

BglII and XhoI and isolated by gel electrophoresis, purified, and cloned into pCaHj483 digested with BamHI and XhoI, resulting in a plasmid which was designated pJaL518. Thus, the construction of the plasmid pJaL518 resulted in a fungal expression plasmid for the *Talaromyces emersonii* AMG gene (Fig. 8).

Construction of the *Aspergillus niger* strain, SMO110

1. Cloning of *A.niger* pyrG gene

10 A library of *A.niger* BO-1 was created in EMBL4 as described by the manufactory instructions. The library was screened with a DIG labelled oligonucleotides (PyrG: 5'-CCCTCACCAGGGGAATGCTGCAGTTGATG- 3' (SEQ ID NO:20) which was designed from the published *Aspergillus niger* sequence (Wilson
15 et al. Nucleic Acids Res. 16, (1988), 2339-2339). A positive EMBL4 clone which hybridized to the DIG probe was isolated from the BO-1 library, and a 3.9 kb XbaI fragment containing the pyrG gene was subcloned from the EMBL4 clone and clone into pUC118 to create pJRoy10.

20

2. Cloning of the *A.niger* glucoamylase (AMG) gene

The above *A.niger* BO-1 library was screened with a DIG labelled PCR fragment generated by amplification on *A.niger* genomic DNA with the following oligonucleotides, 950847:

25 5'-CGCCATTCTCGGCGACTT-3' (SEQ ID NO:21), and
oligonucleotide 951216:

5'-CGCCGCGGTATTCTGCAG-3' (SEQ ID NO:22), which was designed from the published *Aspergillus niger* sequence (Boel et al., EMBO J. 3, (1984), 1581-1585). A positive EMBL4 clone which
30 hybridized to the DIG probe was isolated from the BO-1 library, and a 4.0 kb SpeI fragment containing the AMG gene was subcloned from the EMBL4 clone and clone into pBluescriptSK+ generating plasmid pJRoy17a.

35 3. Construction of the *A. niger* AMG Disruption Cassette

A 2.3 kb SpeI-XhoI fragment containing pyrG was gel isolated from pJRoy10 and the restricted ends filled in with Klenow polymerase. The fragment was inserted into the BglII

site of pJRoy17 which cuts within the AMG gene creating plasmid pSMO127 (Fig. 9). Between the two SpeI sites of pSMO127a is contained the 2.3 kb pyrG gene flanked by 2.2 kb and 2.3 kb 5' and 3' AMG, respectively.

5

4. Construction of a *A. niger* strain disrupted for AMG, SMO110

A.niger JRoyP3 is a spontaneously pyrG mutant of *A.niger* BO-1, which was selected for the growth on a plate containing 5'-fluoro-orotic acid (5'-FOA). The pyrG gene encodes
10 orotidine 5'-phosphate carboxylase and its deficient mutant can be characterized as uridine auxotroph. The identity of pyrG mutant was confirmed by the complementation of the growth on a minimal medium with *A.nidulans* pyrG gene.

Twenty micrograms of the plasmid pSMO127 was digested with
15 SpeI. The DNA was resolved on an 0.8% agarose gel and the 6 kb consisting of the linear disruption cassette was gel isolated.

The linear DNA was transformed into strain JRoyP3.

Genomic DNA was prepared from 200 transformants which was then digested with SpeI. The gel-resolved DNA was transferred to a
20 hybond nylon filter, and hybridized to a non-radioactive DIG probe consisting of the AMG open reading frame. A gene replacement of the disruption cassette into the AMG locus would result in an increase of the wild type 4 kb AMG band to 6.3 kb, an increase due to the 2.3 kb pyrG gene. One transformant #110
25 with the above characteristics was selected for further analysis.

The transformant #110 were grown in 25 ml shake flasks containing YPM media. Strains BO-1 and parent strain JRoyP3 were grown as AMG producing controls. After 3 days, 30µl of
30 clear supernatants were run on a 8-16% SDS PAGE Novex gel. No AMG band was seen in transformant #110, while large bands of AMG were produced in the positive control strain BO-1 and parent strain JRoyP3. Transformant #110 was named SMO110.

35 Expression of *Talaromyces emersonii* AMG in *Aspergillus oryzae* and *Aspergillus niger*

The strains JaL228 and SMO110 was transformed with pJaL518 as described by Christensen et al.; Biotechnology 1988 6 1419-1422.

Typically, *A. oryzae* mycelia was grown in a rich nutrient broth. The mycelia were separated from the broth by filtration. The enzyme preparation Novozyme[®] (Novo Nordisk) was added to the mycelia in osmotically stabilizing buffer such as 1.2 M MgSO₄,
5 buffered to pH 5.0 with sodium phosphate. The suspension was incubated for 60 minutes at 37°C with agitation. The protoplast was filtered through mira-cloth to remove mycelial debris. The protoplast was harvested and washed twice with STC (1.2 M sorbitol, 10 mM CaCl₂, 10 mM Tris-HCl pH 7.5). The protoplast
10 was finally resuspended in 200-1000 µl STC.

For transformation 5 µg DNA was added to 100 µl protoplast suspension and then 200 µl PEG solution (60% PEG 4000, 10 mM CaCl₂, 10 mM Tris-HCl pH 7.5) was added and the mixture was incubated for 20 minutes at room temperature. The protoplast
15 were harvested and washed twice with 1.2 M sorbitol. The protoplast was finally resuspended 200 µl 1.2 M sorbitol, plated on selective plates (minimal medium + 10 g/l Bacto-Agar (Difco), and incubated at 37°C. After 3-4 days of growth at 37°C, stable transformants appear as vigorously growing and sporulating
20 colonies. Transformants was spore isolated twice.

Transformants was grown in shake flask for 4 days at 30°C in 100 ml YPM medium (2 g/l yeast extract, 2 g/l peptone, and 2% maltose). Supernatants were tested for AMG activity as described and analyzed on SDS page gel (Fig. 10).

25

EXAMPLE 7

Removal of the four introns from the *Talaromyces emersonii* AMG DNA sequence for expression in yeast.

For each exon a PCR reaction was made with primers
30 containing overlap to the next exon. Tal 1 and Tal 4 contain an overlap with the yeast vector pJS0026.

Exon 1: Tal 1 was used as the 5' primer and Tal 5 as the 3' primer and the genomic sequence coding for AMG was used as the template. Exon 2: Tal 6 was used as the 5' primer and Tal 7 was
35 used as the 3' primer and the genomic sequence coding for AMG was used as the template. Exon 3: Tal 8 was used as the 5'

primer and Tal 9 was used as the 3' primer and the genomic sequence coding for AMG was used as the template. Exon 4: Tal 10 was used as the 5' primer and Tal 11 was used as the 3' primer and the genomic sequence coding for AMG was used as the template. Exon 5: Tal 12 was used as the 5' primer and Tal 4 was used as the 3' primer and the genomic sequence coding for AMG was used as the template.

A final PCR reaction was performed to combine the 5 exons to a sequence containing the complete coding sequence. In this PCR reaction the 5 fragments from the first PCR reactions were used as template and Tal 1 was used as the 5' primer and Tal4 was used as the 3' primer.

This final PCR fragment containing the coding region was used in an in vivo recombination in yeast together with pJS0026 cut with the restriction enzymes SmaI(or BamHI) and XbaI (to remove the coding region and at the same time create an overlap of about 20 bp in each end to make a recombination event possible).

Tal 1: 5'-CAA TAT AAA CGA CGG TAC CCG GGA GAT CTC CAC CATG GCG TCC CTC GTT G-3' (SEQ ID NO:23);

Tal 4: 5'-CTA ATT ACA TCA TGC GGC CCT CTA GAT CAC TGC CAA CTA TCG TC-3' (SEQ ID NO:24);

Tal 5: 5'-AAT TTG GGT CGC TCC TGC TCG-3' (SEQ ID NO:25);

Tal 6: 5'-CGA GCA GGA GCG ACC CAA ATT ATT TCT ACT CCT GGA CAC G-3' (SEQ ID NO: 26);

Tal 7: 5'-GAT GAG ATA GTT CGC ATA CG-3' (SEQ ID NO: 27);

Tal 8: 5'-CGT ATG CGA ACT ATC TCA TCG ACA ACG GCG AGG CTT CGA CTG C-3' (SEQ ID NO:28);

Tal 9: 5'-CGA AGG TGG ATG AGT TCC AG-3' (SEQ ID NO: 29);

Tal 10: 5'-CTG GAA CTC ATC CAC CTT CGA CCT CTG GGA AGA AGT AGA AGG-3' (SEQ ID NO: 30)

Tal 11: 5'-GAC AAT ACT CAG ATA TCC ATC-3' (SEQ ID NO: 31)

Tal 12: 5'-GAT GGA TAT CTG AGT ATT GTC GAG AAA TAT ACT CCC TCA GAC G-3' (SEQ ID NO: 32)

35

EXAMPLE 8

Expression of *Talaromyces emersonii* glucoamylase in yeast

To express *Talaromyces emersonii* AMG in the yeast

Saccharomyces cerevisiae YNG318 the yeast expression vector pJSO26 was constructed as described in the "Material and Methods" section above.

PJSO26 comprising the DNA sequence encoding the *Talaromyces* AMG was transformed into the yeast by standard methods (cf. Sambrooks et al., (1989), Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor)

The yeast cells were grown at 30°C for 3 days in Sc-ura medium followed by growth for 3 days in YPD. The culture was then centrifuged and the supernatant was used for the thermostability assay described in the "Materials and Method" section.

15 Thermal stability of the *Talaromyces* AMG expressed in yeast at 68°C.

The fermentation broth of the *Talaromyces emersonii* AMG expressed in yeast (*Saccharomyces cerevisiae* YNG318) was used for determination of the thermal stability at 68°C using the method described above under "Determination of thermal stability II". The result of the test is shown in Figure 12.

EXAMPLE 9

25 Purification of recombinant *Talaromyces* AMG produced using *A. niger* HowB112

200 ml culture broth from fermentation of *A. niger* HowB112 harboring the *Talaromyces emersonii* gene was centrifuged at 9000 rpm and dialyzed against 20 mM NaOAc, pH 5 over night. The solution was then applied on a S Sepharose column (200 ml) previously equilibrated in 20 mM NaOAc, pH 5. The glucoamylase was collected in the effluent, and applied on a Q Sepharose column (50 ml) previously equilibrated in 20 mM NaOAc, pH 4.5. Unbound material was washed off the column and the glucoamylase was eluted using a linear gradient from 0-0.3 M NaCl in 20 mM NaOAc over 10 column volumes. Purity of the glucoamylase fraction was checked by SDS-PAGE and only one single band was seen. The molecular weight was again found to about 70 kdal as

seen for the wild type glucoamylase. The specific activity towards maltose was measured and a specific activity of 8.0 AGU/mg (37°C) and 21.0 AGU/mg (60 °C) were found which is in accordance the data on the wild type enzyme.

5

EXAMPLE 10Kinetic Parameters

Kinetic Parameters for Hydrolysis of Maltose and Isomaltose by *Aspergillus niger* AMG and the recombinant *Talaromyces emersonii* AMG expressed in *A. niger*.

10

Maltose	k_{cat} (s ⁻¹) ^a	K_m (mM)	k_{cat}/K_m (s ⁻¹ mM ⁻¹)
<i>Talaromyces emersonii</i>	30.6	3.8	8.1
<i>Aspergillus niger</i>	10.7	1.2	8.8

^a At 45°C uusing 0.05 M NaOAc, pH 4.5

15

Isomaltose	k_{cat} (s ⁻¹) ^a	K_m (mM)	k_{cat}/K_m (s ⁻¹ mM ⁻¹)
<i>Talaromyces emersonii</i>	2.70	53.6	0.050
<i>Aspergillus niger</i>	0.41	19.8	0.021

^a At 45°C uusing 0.05 M NaOAc, pH 4.5

20

EXAMPLE 11

Saccharification performance of recombinant *Talaromyces emersonii* AMG produced in *A. niger*

25 The saccharification performance of the *Talaromyces emersonii* glucoamylase was tested at different temperatures with and without the addition of acid α -amylase and pullulanase. Saccharification was run under the following conditions:

30 Substrate: 10 DE Maltodextrin, approx. 30% DS (w/w)

Temperatures: 60, 65, or 70°C

Initial pH: 4.5

Enzyme dosage:

Recombinant *Talaromyces emersonii* glucoamylase produced in *A.*

35 *niger*: 0.24 or 0.32 AGU/g DS

Acid α -amylase derived from *A. niger*: 0.020 AFAU/g DS

Pullulanase derived from *Bacillus*: 0.03 PUN/g DS

When used alone *Talaromyces* AMG was dosed at the high dosage (0.32 AGU/g DS), otherwise at the low dosage, i.e., 0.24 AGU/g DS.

5 Saccharification

The substrate for saccharification was made by dissolving maltodextrin (prepared from common corn) in boiling Milli-Q water and adjusting the dry substance to approximately 30% (w/w). pH was adjusted to 4.5 (measured at 60°C). Aliquots of substrate corresponding to 150g dry solids were transferred to 500 ml blue cap glass flasks and placed in a water bath with stirring at the respective temperatures. Enzymes were added and pH readjusted if necessary (measured at incubation temperature). Samples were taken periodically and analysed at HPLC for determination of the carbohydrate composition.

The glucose produced during saccharification are given in the table below, the first three columns representing the saccharification with glucoamylase and acid α -amylase and pullulanase, the last three with glucoamylase alone. Numbers are % DP1 on DS.

Time (hours)	0.24 AGU+0.02AFAU+0.03PUN			0.32 AGU		
	60°C	65°C	70°C	60°C	65°C	70°C
24	88.96	90.51	87.91	84.98	86.28	84.35
48	94.03	94.28	91.90	88.86	89.51	86.98
72	95.08	94.75	93.12	90.18	90.42	87.99
98	95.03	94.59	93.64	90.65	90.72	88.51

A glucose yield above 95% was obtained after 72 hours using an enzyme dosage of 0.24 AGU/g DS which is corresponding to 0.03 mg/g DS. The typical dosage of *A. niger* AMG would be 0.18 AGU/g DS which is corresponding to 0.09 mg/g DS to get a yield of 95-96% glucose. A significantly lower enzyme dosage on mg enzyme protein of *Talaromyces* AMG is therefore required in the saccharification process compared to *A. niger* AMG due to the high specific activity of *T. emersonii* AMG.

Example 12

Temperature stability - T½ (half-life) of recombinant
Talaromyces emersonii AMG expressed in yeast

5 The thermal stability of recombinant *Talaromyces emersonii*
glucoamylase expressed in yeast (purified using the method
described in Example 9) was determined at 70°C, pH 4.5, 0.2
AGU/ml using the method described above in the "Material and
Methods" section as "Thermal Stability I (T½ (half-life)
determination of AMG".

10 Figure 13 shows the result of the test. The T½ of the
recombinant *Talaromyces emersonii* glucoamylase expressed in
yeast was determined to about 110 minutes at 70°C.

Applicant's or agent's file reference number	International application N ^o _____
---	--

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>2</u> , line <u>33</u> .	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution CENTRAALBUREAU VOOR SCHIMMELCULTURES	
Address of depositary institution (including postal code and country) Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, The Netherlands	
Date of deposit 2 June 1997	Accession Number CBS 793.97
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No 71. Also, for Canada we request that only an independent expert nominated by the Commissioner is authorized to have access to a sample of the microorganism deposited.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input type="checkbox"/>	This sheet was received with the international application
Authorized officer <i>Perle Anders Paulsen</i>	

For International Bureau use only	
<input type="checkbox"/>	This sheet was received by the International Bureau on:
Authorized officer	

CLAIMS

1. An isolated enzyme with glucoamylase activity having a $T_{1/2}$ (half-life) of at least 100 minutes in 50 mM NaOAc, 0.2 AGU/ml, pH 4.5, at 70°C.
- 5 2. The enzyme according to claim 1, which enzyme has a $T_{1/2}$ in the range from 100-140 minutes, in particular around 120 minutes.
3. An isolated enzyme with glucoamylase activity having an
10 increased specific activity towards maltose at 60°C in comparison to *A.niger* AMG.
4. The enzyme according to claims 1-3, which enzyme has a molecular weight of about 70 kDa determined by SDS-PAGE.
- 15 5. The enzyme according to any of claims 1-4, which enzyme has a pI below 3.5 determined by isoelectrical focusing.
6. The enzyme according to any of claims 1-5 which enzyme is
20 derived from a fungal organism, in particular a filamentous fungus.
7. The enzyme according to claim 6, wherein the filamentous fungus is a strain of the genus *Talaromyces*, in particular a
25 strain of *Talaromyces emersonii*, especially *Talaromyces emersonii* CBS 793.97.
8. An isolated enzyme with glucoamylase activity comprising one or more of the partial sequences shown in SEQ ID NOS: 1-6 or the
30 full length sequence shown in SEQ ID NO: 7 or an enzyme with glucoamylase activity being substantially homologous thereto.
9. The isolated enzyme according to claim 8, wherein the homologous enzyme is at least 80%, at least 90%, more preferably
35 at least 95%, more preferably at least 97%, and most preferably at least 99% with the mature part of the partial amino acid sequences shown in SEQ ID NO: 1-6, or the full length sequence

shown in SEQ ID NO: 7.

10. The isolated enzyme according to claims 8 or 9, which enzyme is derived from a fungal organism, in particular a strain of the
5 filamentous fungus genus *Talaromyces*, in particular *T. emersonii*, especially the deposited *T. emersonii* CBS 793.97.

11. The isolated enzyme according to claims 8-10, wherein said enzyme has improved thermostability and/or increased specific
10 activity compared to the wild-type *A. niger* glucoamylase shown in SEQ ID NO: 9.

12. The isolated enzyme according to any of claims 8-10, which enzyme has the characteristics of any of claims 1-5.

15

13. A cloned DNA sequence encoding an enzyme exhibiting glucoamylase activity, which DNA sequence comprises:

(a) the glucoamylase encoding part of the DNA sequence shown in SEQ ID NO: 33;

20 (b) the DNA sequence shown in positions 649-2724 in SEQ ID NO:33 or its complementary strand;

(c) an analogue of the DNA sequence defined in (a) or (b) which is at least 80% homologous with said DNA sequence;

25 (d) a DNA sequence which hybridizes with a double-stranded DNA probe comprising the sequence shown in 649-2724 in SEQ ID NO: 33 at low stringency;

(e) a DNA sequence which, because of the degeneracy of the genetic code, does not hybridize with the sequences of (b) or (f), but which codes for a polypeptide having exactly the same
30 amino acid sequence as the polypeptide encoded by any of these DNA sequences; or

(g) a DNA sequence which is a fragment of the DNA sequences specified in (a), (b), (c), (d), or (e).

35 14. The DNA sequence of claim 13, wherein the DNA sequence is derived from fungal organism, in particular a strain of the filamentous fungus genus *Talaromyces*, in particular *T. emersonii*, especially the deposited *T. emersonii* CBS 793.97.

15. A process for converting starch or partially hydrolyzed starch into a syrup containing dextrose, said process including the step of saccharifying starch hydrolyzate in the presence of
5 a glucoamylase according to any of claims 1-12 or a glucoamylase encoded by a DNA sequence of claims 13 or 14.

16. The process of claim 15, wherein the dosage of glucoamylase is present in the range from 0.05 to 0.5 AGU per gram of dry
10 solids.

17. The process of any claims 15 or 16, comprising saccharification of a starch hydrolyzate of at least 30 percent by weight of dry solids.

15

18. The process of any of the preceding claims, wherein the saccharification is conducted in the presence of a debranching enzyme selected from the group of pullulanase and isoamylase, preferably a pullulanase derived from *Bacillus acidopullulyticus*
20 or *Bacillus deramificans* or an isoamylase derived from *Pseudomonas amyloclavata*.

19. The process of any of the preceding claims, wherein the saccharification is conducted at a pH of about 3 to 5.5 and at a
25 temperature of 60-80°C, preferably 63-75°C, for 24 to 72 hours, preferably for 36-48 hours at a pH from 4 to 4.5.

20. A method of saccharifying a liquefied starch solution, which method comprises an enzymatic saccharification step using a
30 glucoamylase according to any of claims 1-12 or a glucoamylase encoded by a DNA sequence of claims 13 or 14.

21. Use of a glucoamylase according to any one of claims 1-12 or or a glucoamylase encoded by a DNA sequence of claims 13 or 14
35 in a starch conversion process.

22. Use of a glucoamylase according to any one of claims 1-12 or or a glucoamylase encoded by a DNA sequence of claims 13 or 14

in a continuous starch conversion process.

23. Use of a glucoamylase according to any one of claims 1-12 or
or a glucoamylase encoded by a DNA sequence of claims 13 or 14
5 in a process for producing oligosaccharides.

24. Use of a glucoamylase according to any one of claims 1-12 or
or a glucoamylase encoded by a DNA sequence of claims 13 or 14
in a process for producing specialty syrups.

10

25. Use of a glucoamylase according to any one of claims 1-12 or
or a glucoamylase encoded by a DNA sequence of claims 13 or 14
in a process for producing ethanol for fuel.

15 26. Use of a glucoamylase according to any one of claims 1-12 or
a glucoamylase encoded by a DNA sequence of claims 13 or 14 in
a process for producing a beverage.

20 27. Use of a glucoamylase according to any one of claims 1-12 or
a glucoamylase encoded by a DNA sequence of claims 13 or 14 in
a fermentation process for producing organic compounds, such as
citric acid, ascorbic acid, lysine, glutamic acid.

25 28. An isolated pure culture of the microorganism *Talaromyces*
emersonii CBS 793.97 or a mutant thereof capable of producing a
glycoamylase as defined in any of the claims 1-12 or a
glucoamylase encoded by a DNA sequence of claims 13 or 14.




Fig. 1
SUBSTITUTE SHEET (RULE 26)

2/18




Fig. 2

3/18




Fig. 3

4/18




Fig. 4

10 30 50 70 90
ACGAGATGTGTATATACTGTGAACCAACTAGATGATGTCAGTTATGCTGGTCTGAGAACTCATAGAACCCCTTGAAAAATACCCCAAGCT
110 130 150 170
AGCACTCCAACCCCTAACTCTGTTGCTCTACTAGATCAAGACGAGTACTCTGATTGAGCTGCAGGCTTGGAATATATGATTAGCAGAAAAA
190 210 230 250 270
GGGTTAAAACTTGTATGACAATCAGTTTGTCTCAGTACTCCGCTAGTGTGATGCCATGTCTATAGAGTCGACACTAAGGCAGCATGTGTAATGAGT
290 310 330 350
CGGAAATGACAGGAAGCAGATTCCCTTAACAGTCATGTTCTCCGTGCCCTGCATCCCCACGTCACCTGCAAGATGCGACGCTACTCCACAC
370 390 410 430 450
CGGCGCCTTGATGCTGCTGTTCCCTGGCCTAGTGGAGCCCCCATGCGCTGCTAGCTCGTGGTCTTCGAATAAATCAGAAATAAAAAACGGAG
470 490 510 530
TAATTAAATTGCGCCCGCAACAACTAAAGCAATGTAACTCAATGCCAAAGCTTCCGCTGATGCTCTTGACATCTCCGTAAGTGGCTTCTTTTCG
550 570 590 610 630
TAATTTTCAGACGTATATATAGTAGTAATGCCCCAGCAGGCCGGGATAATGATGGGGAATTCTGAACCTCTCAGCTTCCGTACGCTGAACAGT
650 670 690 710
TTGCTTGCCTGTCAACCATGGCGTCCCTCGTTGCTGGCGCTCTCTGCATCCTGGCCCTGACGCCCTGCTGCATTGTCACGAGCGCCCGTT
730 750 770 790 810
M A S L V A G A L C I L G L T P A A F A R A P V
.....

GCAGCGGAGCCACCGGTTCCTGGACTCCTTTCTCGCAACCGAACTCCAATTGCCCTCCAAGCGTGCTGAACAACATCGGCCCAAT
A A R A T G S L D S F L A T E T P I A L Q G V L N N I G P N
830 850 870 890
GGTGTGATGTGGCAGGAGCAAGCGCGGCATTTGTGGTTGCCAGTCCGAGCAGGAGCGACCCCAAATTgtaggttctttcccaccagaat
G A D V A G A S A G I V V A S P S R S D P N 970 990
910 930 950
tacttattaaatcagccctctgacaggttgaagATTCTACTCCTGGACACGTGACGCGCTCACGGCCAAATACCTCGTCGACGCC
Y F Y S W T R D A A L T A K Y L V D A
1010 1030 1050 1070
TTCATCGCGGCAACAAGGACCCTAGAGCAGACCATCCAGCAGTACATCAGCGCGCAGCGAAGTGCAAACTATCTCCAATCCGTCCGGA
F I A G N K D L E Q T I Q Q Y I S A Q A K V Q T I S N P S G
1090 1110 1130 1150 1170
GATTATCCACCGGTGGCTTAGGTGAGCCCCAAGTTCAATGTGAATGAGACGGCTTTACCGGGCCCTGGGGTCTCCACAGAGGGACGGA
D L S T G G L G E P K F N V N E T A F T G P W G R P Q R D G
1190 1210 1230 1250
CCAGCGTTGAGAGCGAGCGCCCTCATTTGCGTATGCGAACTATCTCATCgttaagcttctgctgccttctctctgctgctatgctaa
P A L R A T A L I A Y A N Y L I 1310 1330 1350
1270 1290
gtagtctgtcagGACAACGGCGAGGCTTCGACTGCCGATGAGATCATCTGGCCGATTGTCCAGAATGATCTGTCTACATCACCACAATA
D N G E A S T A D E I I W P I V Q N D L S Y I T Q Y
1370 1390 1410 1430
CTGGAACTCATCCACCTTCGgtaggcaaatgaatatccccgacacagcggtgtactaatgtgattcagACCTCTGGGAAGAAGTAGAAGG
W N S S T F 1470 1490 1510 1530
1450

7/18

ATCCTCATTTTCACAACCGCCGTGCAACACCGCGCCCTGGTCTGAAGGCAATGCACTGGCAACAAGGCTGAACCAACACACGTGCTCCAACCTG
 S S F F T T A V Q H R A L V E G N A L A T R L N H T C S N C
 1550 1570 1590 1610
 CGTCTCTCAGGCCCCCTCAGGTCCTGTGTTTCCCTGCAGTCATACTGGACCGGATCGTATGTTCTGGCCAACTTTGGTGGCAGCGGTCGTTC
 V S Q A P Q V L C F L Q S Y W T G S Y V L A N F G G S G R S
 1630 1650 1670 1690 1710
 CCGCAAGGACGTGAATTCGATTCTGGGCAGCATCCACACCTTTGATCCCGCGGAGGCTGTGACGACTCGACCTTCCAGCCGTGTTCTGGC
 G K D V N S I L G S I H T F D P A G G C D D S T F Q P C S A
 1730 1750 1770 1790
 CCGTGCCCTTGGCAATCACAAGGTGGTCAACCGACTCGTTCGGAGTATCTATGCGATCAACTCAGGCATCGCAGAGGGATCTGCCGTGGC
 R A L A N H K V V T D S F R S I Y A I N S G I A E G S A V A
 1810 1830 1850 1870 1890
 AGTCGGCCGCTACCCCTGAGGATGTCTACCAGGGGGGAACCCCTGGTACCTGGCCACAGCAGCGGCTGCAGAGCAGCTTTACGACGCCAT
 V G R Y P E D V Y Q G G N P W Y L A T A A A E Q L Y D A I
 1910 1930 1950 1970
 CTACCAGTGGGAAGATCGGCTCGATAAGTATCACGGACGTTAGTCTGCCATTTTCCAGGATATCTACCCCTTCTGCCGCGGTGGGCAC
 Y Q W K K I G S I S I T D V S L P F F Q D I Y P S A A V G T
 1990 2010 2030 2050 2070
 CTATAACTCTGGCTCCACGACTTTCAACGACATCATCTCGGCCGTCCAGACGATGGTGATGGATATCTGAGTATTGTCgtacgttttgc
 Y N S G S T T F N D I I S A V Q T Y G D G Y L S I V
 2090 2110 2130 2150

Fig. 5 (Continued)

cttagattctcaggtgtaagaaaaaatggaactaactcagttctagGAGAAATATACTCCCTCAGACGGCTCTCTTACCGAACAATTC
2170
E K Y T P S D G S L T E Q F 2250
2210
TCCCGTACAGCGCACTCCGCTTCTGCCTCTGCCCCTGACTTGGTCGTACGCTTCTCTCCTAACCGCTTCGGCCCCGACAGACAGTCCGTC
S R T D G T P L S A S A L T W S Y A S L L T A S A R R Q S V 2330
2290
GTCCCTGCTTCCTGGGGCGAAAGCTCCGCAAGCAGCGTCCCTGCCGTCTGCTCTGCCACCTCTGCCACGGGGCCCATACAGCAGCGGTACC
V P A S W G E S S A S S V P A V C S A T S A T G P Y S T A T 2430
2370
AACACCGTCTGGCCAAGCTCTGGCTCTGGCAGCTCAACAACCAACAGTAGCGCCCCATGCACCACTCCTACCTCTGTGGCTGTGACCTTC
N T V W P S S G S S T T T S S A P C T T P T S V A V T F 2510
2470
GACGAAATCGTCAGCACCAAGTTACGGGGAGACAATCTACCTGGCCGGCTCGATCCCCGAGCTGGGCAACTGGTCCACGGCCAGCGGATC
D E I V S T S Y G E T I Y L A G S I P E L G N W S T A S A I 2610
2550
CCCCCTCCGGCGGATGCTTACACCAACAGCAACCCGCTCTGGTACGTGACCGTCAATCTGCCCCCTGGCACCAAGCTTCGAGTACAAGTTC
P L R A D A Y T N S N P L W Y V T V N L P P G T S F E Y K F 2690
2650
TTCAAGAACAGACGGACGGACCATCGTCTGGGAAGACGACCCGAACCGGTCTGTACACGGTCCAGCGTACTGTGGGCAGACTACCGCC
F K N Q T D G T I V W E D D P N R S Y T V P A Y C G Q T T A 2730
2710
ATTCTTGACGATAGTTGGCAGTGAGATAACATCCACCCCTTCTGTTTA
I L D D S W Q *

Fig. 5 (Continued)

1
 An amg-1. PRO
 Ao AMG. PRO
 Tal-AMG. PRO
 60
 M.SF.RSLALSGLVCTGLA.NVISKRAT..LDSWLSNEATVARTAILNNIGADGAWVSG
 MVSF.SSCLRALALGSSVLAVQPVLRQATG.LDTWLSTEANFSRQAILNNIGADGQSAQG
 MASLVAGALCILGLTPAAFARAPVAARATGSLDSFLATETPIALQGVLLNNIGPNGADVAG
 * * * * *
 120
 61
 ADSGIVVASPSTNDPDYFYTWTRDSGLVLKTLVDLFRNGDTSLLSTIENYISAQAIVQGI
 ASPGVVIASPSKSDPDYFYTWTRDSGLVMKTLVDLFRGGDADLLPIIEEFISSQARIQGI
 ASAGIVVASPSRSDPNYFYSWTRDAALTAKYLVDAFIAGNKDLEQTIQQYISAQAKVQTI
 * * * * *
 180
 121
 SNPSGDLSSGAGLGEPKFNVDETAYTGSWGRPQRDGPALRATAMIGFGQWLLDNGYTSTA
 SNPSGALSSG.GLGEPKFNVDETAFTGAWGRPQRDGPALRATAMISFGEWLVENSHTSIA
 SNPSGDLSTG.GLGEPKFNVDETAFTGPWGRPQRDGPALRATALIAYANYLIDNGEASTA
 * * * * *
 240
 181
 TDI VWPLVRNDLSYVAQYWNQTYDLWEEVNGSSFFETIAVQHRALVEGSAFATAVGSSCS
 TDLVWPVVRNDLSYVAQYWSQSGFDLWEEVQGTSTFTVAVSHRALVEGSSFAKTVGSSCP
 DEIIWPIVQNDLSYITQYWNSSSTFDLWEEVEGSSFTTAVQHRALVEGNALATRLNHTCS
 * * * * *
 300
 241
 WCDSQAPEILCYLQSEFWTGSFILANFDS.SRSGKDANTLLGSIHTFDPEAACDDSTFQPC
 YCDSQAPQVRCYLQSEFWTGSYIQANFEGG.GRSGKDINTVLGSIHTFDPPQATCDDATFQPC
 NCVSQAPQVLCFLQSYWTGSYVLANFGGSRSGKDVNSILGSIHTFDPAGGCDSTFQPC
 * * * * *
 360
 301

10/18

```

An  amg-1. PRO
Ao  AMG. PRO
Tal-AMG. PRO

SPRALANHKEVDSFRSIYTLNDGLSDSEAVAVGRYPEDTYYNGNPWFELCTLA AA EQLYD
SARALANHKVVTD SFRSIYAINSGRAENQAVAVGRYPEDSYNGNPWFELTTLA AA EQLYD
SARALANHKVVTD SFRSIYAINSGIAEGSAVAVGRYPEDVYQGGNPWYLATA AA EQLYD
* * * * *
361
ALYQWDKQGSLEVTDVSLDFFKALYSDAATGTYS SSSSTYSIVDAVKTFADGFVSIVET
ALYQWDKIGSLAITDVSLPFFKALYSSAATGTYASSTTVYKDIVSAVKAYADGYVQIVQT
AIYQWKKIGSISITDVSLPFFQDIYPSAAVGTYN SGSTTFNDIISAVQTYGDGYLSIVEK
* * * * *
420
421
HAASNGMSEQYDKSDGEQLSARDLTWSYAALLTANNRRNSVVPASWGETSASSVPGTCA
YAASTGSMAEQYTKTDGSGQSARDLTWSYAALLTANNRRNAVVPAPWGETAATSIPSACS
YTPSDGSLTEQFSRTDGTPLSASALTWSYASLLTASARRQSVVPASWGESSASSVPAVCS
* * * * *
480
481
ATSAIGTYSSVTVTSWPSIVATGGTTTATPTGSGSVTSTSKTTATASKTSTSTSTSC
TTSASGTYSSVVTTSWPTISGYPGA. . . . . PDSPCQ
ATSATGPYSTATNTVWPS. . . . . SGSGS. . . . . STTSSAPCT
* * * * *
540
541
TPTAVAVTFDLTATTYGENIYLVGSIQLGDWETSDGIALSADKYTSSDPLWYVTVTL
VPTTVSVTFEAVKATTVYGESIKIVGSIQLGSWNPSSATALNADSYTTDNPLWTGTINLP
TPTSVAVTFDEIVSTSYGETIYLAGSIPELGNWSTASAIPLRADAYTNSNPLWYVTVNLP
* * * * *
600
601
AGESFEYKFIRIESDDSVEWESDPNREYTPQACGTSTATVTD TWR
AGQSF EYKFIRVQ. NGAVTWESDPNRKYTPSTCGVKS AVQSDVWR
PGTSFEYKFFKNQTDGTIVWEDDPNRSYTPAYCGQT TAILDDSWQ
* * * * *

```

Fig. 6 (Continued)

11/18




Fig. 7

12/18




Fig. 8




Fig. 9




Fig. 9 (Continued)

15/18




Fig. 10

SUBSTITUTE SHEET (RULE 26)




Fig. 11




Fig. 12




Fig. 13

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- (i) APPLICANT:
- 5 (A) NAME: Novo Nordisk A/S
(B) STREET: Novo Alle
(C) CITY: Bagsvaerd
(E) COUNTRY: Denmark
(F) POSTAL CODE (ZIP): DK 2880
10 (G) TELEPHONE: +45 4444 8888
(H) TELEFAX: +45 4449 3256
- (ii) TITLE OF INVENTION: Thermostable glucoamylase
- (iii) NUMBER OF SEQUENCES: 6
- (iv) COMPUTER READABLE FORM:
- 15 (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
- 20 (2) INFORMATION FOR SEQ ID NO: 1:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
25 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (vi) ORIGINAL SOURCE:
- (B) STRAIN: Talaromyces emersonii CBS 793.97
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
- 30 Ala Asn Gly Ser Leu Asp Ser Phe Leu Ala Thr Glu Xaa Pro Ile Ala
1 5 10 15
- Leu Gln Gly Val Leu Asn Asn Ile Gly
35 20 25
- (2) INFORMATION FOR SEQ ID NO: 2:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 amino acids
40 (B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (vi) ORIGINAL SOURCE:
- 45 (B) STRAIN: Talaromyces emersonii CBS 793.97
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
- Val Gln Thr Ile Ser Asn Pro Ser Gly Asp Leu Ser Thr Gly Gly Leu
1 5 10 15
- 50 Gly Glu Pro Lys
20
- (2) INFORMATION FOR SEQ ID NO: 3:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 22 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
60 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (vi) ORIGINAL SOURCE:
- (B) STRAIN: Talaromyces emersonii CBS 793.97
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
- 65 Xaa Asn Val Asn Glu Thr Ala Phe Thr Gly Pro Xaa Gly Arg Pro Gln
1 5 10 15
- Arg Asp Gly Pro Ala Leu

20

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(B) STRAIN: *Talaromyces emersonii* CBS 793.97

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Asp Val Asn Ser Ile Leu Gly Ser Ile His Thr Phe Asp Pro Ala Gly
 1 5 10 15
 Gly Cys Asp Asp Ser Thr Phe Gln Pro Cys Ser Ala Arg Ala Leu Ala
 20 25 30
 Asn His Lys
 35

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(B) STRAIN: *Talaromyces emersonii* CBS 793.97

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Thr Xaa Ala Ala Ala Glu Gln Leu Tyr Asp Ala Ile Tyr Gln Trp Lys
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

(B) STRAIN: *Talaromyces emersonii* CBS 793.97

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Ala Gln Thr Asp Gly Thr Ile Val Trp Glu Asp Asp Pro Asn Arg Ser
 1 5 10 15
 Tyr Thr Val Pro Ala Tyr Cys Gly Gln Thr Thr Ala Ile Leu Asp Asp
 20 25 30
 Ser Trp Gln
 35

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 591 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(B) STRAIN: *Talaromyces emersonii* CBS 793.97

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Ala Thr Gly Ser Leu Asp Ser Phe Leu Ala Thr Glu Thr Pro Ile Ala

	1	5	10	15
	Leu	Gln	Gly	Val
		20		
	Leu	Asn	Asn	Ile
			25	
	Gly	Pro	Asn	Gly
				30
	Ala	Asp	Val	Ala
5	Gly	Ala	Ser	Ala
		35		
	Gly	Ile	Val	Val
			40	
	Ala	Ser	Pro	Ser
				45
	Arg	Ser	Asp	Pro
10	Asn	Tyr	Phe	Tyr
		50		
	Ser	Trp	Thr	Arg
			55	
	Asp	Ala	Ala	Leu
				60
	Thr	Ala	Lys	Tyr
	Leu	Val	Asp	Ala
			70	
	Phe	Asn	Arg	Gly
				75
	Asn	Lys	Asp	Leu
				80
	Glu	Gln	Thr	Ile
15	Gln	Gln	Tyr	Ile
			85	
	Ser	Ala	Gln	Ala
				90
	Lys	Val	Gln	Thr
				95
	Ser	Gly	Asp	Leu
			100	
	Ser	Thr	Gly	Gly
				105
	Leu	Gly	Glu	Pro
				110
	Lys	Phe	Asn	Val
20	Asn	Glu	Thr	Ala
			115	
	Phe	Thr	Gly	Pro
				120
	Trp	Gly	Arg	Pro
				125
	Gln	Arg	Asp	Gly
25	Pro	Ala	Leu	Arg
			130	
	Ala	Thr	Ala	Leu
				135
	Ile	Ala	Tyr	Ala
				140
	Asn	Tyr	Leu	Ile
	Asp	Asn	Gly	Glu
			145	
	Ala	Ser	Thr	Ala
				150
	Asp	Glu	Ile	Ile
				155
	Trp	Pro	Ile	Val
				160
30	Gln	Asn	Asp	Leu
			165	
	Ser	Tyr	Ile	Thr
				170
	Gln	Tyr	Trp	Asn
				175
	Ser	Ser	Thr	Phe
	Asp	Leu	Trp	Glu
			180	
	Glu	Val	Glu	Gly
				185
	Ser	Ser	Phe	Phe
				190
	Thr	Thr	Ala	Val
35	Gln	His	Arg	Ala
			195	
	Leu	Val	Glu	Gly
				200
	Asn	Ala	Leu	Ala
				205
	Thr	Arg	Leu	Asn
	His	Thr	Cys	Ser
			210	
	Asn	Cys	Val	Ser
				215
	Gln	Ala	Pro	Gln
				220
	Val	Leu	Cys	Phe
40	Leu	Gln	Ser	Tyr
			225	
	Trp	Thr	Gly	Ser
				230
	Tyr	Val	Leu	Ala
				235
	Asn	Phe	Gly	Gly
				240
45	Ser	Gly	Arg	Ser
			245	
	Lys	Asp	Val	Asn
				250
	Ser	Ile	Leu	Gly
				255
	Ser	Ile	His	
	Thr	Phe	Asp	Pro
			260	
	Ala	Gly	Gly	Cys
				265
	Asp	Asp	Ser	Thr
				270
	Phe	Gln	Pro	Cys
50	Ser	Ala	Arg	Ala
			275	
	Leu	Ala	Asn	His
				280
	Lys	Val	Val	Thr
				285
	Asp	Ser	Phe	Arg
	Ser	Ile	Tyr	Ala
			290	
	Ile	Asn	Ser	Gly
				295
	Ile	Ala	Glu	Gly
				300
	Ser	Ala	Val	Ala
55	Val	Gly	Arg	Tyr
			305	
	Pro	Glu	Asp	Val
				310
	Tyr	Gln	Gly	Gly
				315
	Asn	Pro	Trp	Tyr
				320
60	Leu	Ala	Thr	Ala
			325	
	Ala	Ala	Ala	Glu
				330
	Gln	Leu	Tyr	Asp
				335
	Ile	Tyr	Gln	
	Trp	Lys	Lys	Ile
				340
	Gly	Ser	Ile	Ser
				345
	Thr	Asp	Val	Ser
				350
	Leu	Pro	Phe	
65	Phe	Gln	Asp	Ile
			355	
	Tyr	Pro	Ser	Ala
				360
	Ala	Val	Gly	Thr
				365
	Tyr	Asn	Ser	Gly

Ser Thr Thr Phe Asn Asp Ile Ile Ser Ala Val Gln Thr Tyr Gly Asp
 370 375 380
 Gly Tyr Leu Ser Ile Val Glu Lys Tyr Thr Pro Ser Asp Gly Ser Leu
 385 390 395 400
 Thr Glu Gln Phe Ser Arg Thr Asp Gly Thr Pro Leu Ser Ala Ser Ala
 405 410 415
 Leu Thr Trp Ser Tyr Ala Ser Leu Leu Thr Ala Ser Ala Arg Arg Gln
 420 425 430
 Ser Val Val Pro Ala Ser Trp Gly Glu Ser Ser Ala Ser Ser Val Leu
 435 440 445
 Ala Val Cys Ser Ala Thr Ser Ala Thr Gly Pro Tyr Ser Thr Ala Thr
 450 455 460
 Asn Thr Val Trp Pro Ser Ser Gly Ser Gly Ser Ser Thr Thr Thr Ser
 465 470 475 480
 Ser Ala Pro Cys Thr Thr Pro Thr Ser Val Ala Val Thr Phe Asp Glu
 485 490 495
 Ile Val Ser Thr Ser Tyr Gly Glu Thr Ile Tyr Leu Ala Gly Ser Ile
 500 505 510
 Pro Glu Leu Gly Asn Trp Ser Thr Ala Ser Ala Ile Pro Leu Arg Ala
 515 520 525
 Asp Ala Tyr Thr Asn Ser Asn Pro Leu Trp Tyr Val Thr Val Asn Leu
 530 535 540
 Pro Pro Gly Thr Ser Phe Glu Tyr Lys Phe Phe Lys Asn Gln Thr Asp
 545 550 555 560
 Gly Thr Ile Val Trp Glu Asp Asp Pro Asn Arg Ser Tyr Thr Val Pro
 565 570 575
 Ala Tyr Cys Gly Gln Thr Thr Ala Ile Leu Asp Asp Ser Trp Gln
 580 585 590

- (2) INFORMATION FOR SEQ ID NO: 8:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1605 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
- (A) DESCRIPTION: /desc = "cDNA"
- (vi) ORIGINAL SOURCE:
- (B) STRAIN: *Aspergillus niger*
- (ix) FEATURE:
- (A) NAME/KEY: sig_peptide
- (B) LOCATION: 1..72
- (ix) FEATURE:
- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 73..1602
- (ix) FEATURE:
- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1602

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

ATG TCG TTC CGA TCT CTA CTC GCC CTG AGC GGC CTC GTC TGC ACA GGG
 Met Ser Phe Arg Ser Leu Leu Ala Leu Ser Gly Leu Val Cys Thr Gly
 -24 -20 -15 -10

	TTG GCA AAT GTG ATT TCC AAG CGC GCG ACC TTG GAT TCA TGG TTG AGC	96
	Leu Ala Asn Val Ile Ser Lys Arg Ala Thr Leu Asp Ser Trp Leu Ser	
5	-5 1 5	
	AAC GAA GCG ACC GTG GCT CGT ACT GCC ATC CTG AAT AAC ATC GGG GCG	144
	Asn Glu Ala Thr Val Ala Arg Thr Ala Ile Leu Asn Asn Ile Gly Ala	
	10 15 20	
10	GAC GGT GCT TGG GTG TCG GGC GCG GAC TCT GGC ATT GTC GTT GCT AGT	192
	Asp Gly Ala Trp Val Ser Gly Ala Asp Ser Gly Ile Val Val Ala Ser	
	25 30 35 40	
15	CCC AGC ACG GAT AAC CCG GAC TAC TTC TAC ACC TGG ACT CGC GAC TCT	240
	Pro Ser Thr Asp Asn Pro Asp Tyr Phe Tyr Thr Trp Thr Arg Asp Ser	
	45 50 55	
20	GGT CTC GTC CTC AAG ACC CTC GTC GAT CTC TTC CGA AAT GGA GAT ACC	288
	Gly Leu Val Leu Lys Thr Leu Val Asp Leu Phe Arg Asn Gly Asp Thr	
	60 65 70	
25	AGT CTC CTC TCC ACC ATT GAG AAC TAC ATC TCC GCC CAG GCA ATT GTC	336
	Ser Leu Leu Ser Thr Ile Glu Asn Tyr Ile Ser Ala Gln Ala Ile Val	
	75 80 85	
30	CAG GGT ATC AGT AAC CCC TCT GGT GAT CTG TCC AGC GGC GCT GGT CTC	384
	Gln Gly Ile Ser Asn Pro Ser Gly Asp Leu Ser Ser Gly Ala Gly Leu	
	90 95 100	
35	GGT GAA CCC AAG TTC AAT GTC GAT GAG ACT GCC TAC ACT GGT TCT TGG	432
	Gly Glu Pro Lys Phe Asn Val Asp Glu Thr Ala Tyr Thr Gly Ser Trp	
	105 110 115 120	
40	GGA CGG CCG CAG CGA GAT GGT CCG GCT CTG AGA GCA ACT GCT ATG ATC	480
	Gly Arg Pro Gln Arg Asp Gly Pro Ala Leu Arg Ala Thr Ala Met Ile	
	125 130 135	
45	GGC TTC GGG CAG TGG CTG CTT GAC AAT GGC TAC ACC AGC ACC GCA ACG	528
	Gly Phe Gly Gln Trp Leu Leu Asp Asn Gly Tyr Thr Ser Thr Ala Thr	
	140 145 150	
50	GAC ATT GTT TGG CCC CTC GTT AGG AAC GAC CTG TCG TAT GTG GCT CAA	576
	Asp Ile Val Trp Pro Leu Val Arg Asn Asp Leu Ser Tyr Val Ala Gln	
	155 160 165	
55	TAC TGG AAC CAG ACA GGA TAT GAT CTC TGG GAA GAA GTC AAT GGC TCG	624
	Tyr Trp Asn Gln Thr Gly Tyr Asp Leu Trp Glu Glu Val Asn Gly Ser	
	170 175 180	
60	TCT TTC TTT ACG ATT GCT GTG CAA CAC CGC GCC CTT GTC GAA GGT AGT	672
	Ser Phe Phe Thr Ile Ala Val Gln His Arg Ala Leu Val Glu Gly Ser	
	185 190 195 200	
65	GCC TTC GCG ACG GCC GTC GGC TCG TCC TGC TCC TGG TGT GAT TCT CAG	720
	Ala Phe Ala Thr Ala Val Gly Ser Ser Cys Ser Trp Cys Asp Ser Gln	
	205 210 215	
70	GCA CCC GAA ATT CTC TGC TAC CTG CAG TCC TTC TGG ACC GGC AGC TTC	768
	Ala Pro Glu Ile Leu Cys Tyr Leu Gln Ser Phe Trp Thr Gly Ser Phe	
	220 225 230	
75	ATT CTG GCC AAC TTC GAT AGC AGC CGT TCC GGC AAG GAC GCA AAC ACC	816
	Ile Leu Ala Asn Phe Asp Ser Ser Arg Ser Gly Lys Asp Ala Asn Thr	
	235 240 245	
80	CTC CTG GGA AGC ATC CAC ACC TTT GAT CCT GAG GCC GCA TGC GAC GAC	864
	Leu Leu Gly Ser Ile His Thr Phe Asp Pro Glu Ala Ala Cys Asp Asp	
	250 255 260	

5	TCC ACC TTC CAG CCC TGC TCC CCG CGC GCG CTC GCC AAC CAC AAG GAG Ser Thr Phe Gln Pro Cys Ser Pro Arg Ala Leu Ala Asn His Lys Glu 265 270 275 280	912
10	GTT GTA GAC TCT TTC CGC TCA ATC TAT ACC CTC AAC GAT GGT CTC AGT Val Val Asp Ser Phe Arg Ser Ile Tyr Thr Leu Asn Asp Gly Leu Ser 285 290 295	960
15	GAC AGC GAG GCT GTT GCG GTG GGT CGG TAC CCT GAG GAC ACG TAC TAC Asp Ser Glu Ala Val Ala Val Gly Arg Tyr Pro Glu Asp Thr Tyr Tyr 300 305 310	1008
20	AAC GGC AAC CCG TGG TTC CTG TGC ACC TTG GCT GCC GCA GAG CAG TTG Asn Gly Asn Pro Trp Phe Leu Cys Thr Leu Ala Ala Ala Glu Gln Leu 315 320 325	1056
25	TAC GAT GCT CTA TAC CAG TGG GAC AAG CAG GGG TCG TTG GAG GTC ACA Tyr Asp Ala Leu Tyr Gln Trp Asp Lys Gln Gly Ser Leu Glu Val Thr 330 335 340	1104
30	GAT GTG TCG CTG GAC TTC TTC AAG GCA CTG TAC AGC GAT GCT GCT ACT Asp Val Ser Leu Asp Phe Phe Lys Ala Leu Tyr Ser Asp Ala Ala Thr 345 350 355 360	1152
35	GGC ACC TAC TCT TCG TCC AGT TCG ACT TAT AGT AGC ATT GTA GAT GCC Gly Thr Tyr Ser Ser Ser Ser Thr Tyr Ser Ser Ile Val Asp Ala 365 370 375	1200
40	GTG AAG ACT TTC GCC GAT GGC TTC GTC TCT ATT GTG GAA ACT CAC GCC Val Lys Thr Phe Ala Asp Gly Phe Val Ser Ile Val Glu Thr His Ala 380 385 390	1248
45	GCA AGC AAC GGC TCC ATG TCC GAG CAA TAC GAC AAG TCT GAT GGC GAG Ala Ser Asn Gly Ser Met Ser Glu Gln Tyr Asp Lys Ser Asp Gly Glu 395 400 405	1296
50	CAG CTT TCC GCT CGC GAC CTG ACC TGG TCT TAT GCT GCT CTG CTG ACC Gln Leu Ser Ala Arg Asp Leu Thr Trp Ser Tyr Ala Ala Leu Leu Thr 410 415 420	1344
55	GCC AAC AAC CGT CGT AAC TCC GTC GTG CCT GCT TCT TGG GGC GAG ACC Ala Asn Asn Arg Arg Asn Ser Val Val Pro Ala Ser Trp Gly Glu Thr 425 430 435 440	1392
60	TCT GCC AGC AGC GTG CCC GGC ACC TGT GCG GCC ACA TCT GCC ATT GGT Ser Ala Ser Ser Val Pro Gly Thr Cys Ala Ala Thr Ser Ala Ile Gly 445 450 455	1440
65	ACC TAC AGC AGT GTG ACT GTC ACC TCG TGG CCG AGT ATC GTG GCT ACT Thr Tyr Ser Ser Val Thr Val Thr Ser Trp Pro Ser Ile Val Ala Thr 460 465 470	1488
70	GGC GGC ACC ACT ACG ACG GCT ACC CCC ACT GGA TCC GGC AGC GTG ACC Gly Gly Thr Thr Thr Ala Thr Pro Thr Gly Ser Gly Ser Val Thr 475 480 485	1536
75	TCG ACC AGC AAG ACC ACC GCG ACT GCT AGC AAG ACC AGC ACC ACG ACC Ser Thr Ser Lys Thr Thr Ala Thr Ala Ser Lys Thr Ser Thr Thr Thr 490 495 500	1584
80	CGC TCT GGT ATG TCA CTG TGA Arg Ser Gly Met Ser Leu 505 510	1605

(2) INFORMATION FOR SEQ ID NO: 9:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 534 amino acids

(B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

5 Met Ser Phe Arg Ser Leu Leu Ala Leu Ser Gly Leu Val Cys Thr Gly
 -24 -20 -15 -10

10 Leu Ala Asn Val Ile Ser Lys Arg Ala Thr Leu Asp Ser Trp Leu Ser
 -5 1 5

Asn Glu Ala Thr Val Ala Arg Thr Ala Ile Leu Asn Asn Ile Gly Ala
 10 15 20

15 Asp Gly Ala Trp Val Ser Gly Ala Asp Ser Gly Ile Val Val Ala Ser
 25 30 35 40

Pro Ser Thr Asp Asn Pro Asp Tyr Phe Tyr Thr Trp Thr Arg Asp Ser
 45 50 55

20 Gly Leu Val Leu Lys Thr Leu Val Asp Leu Phe Arg Asn Gly Asp Thr
 60 65 70

25 Ser Leu Leu Ser Thr Ile Glu Asn Tyr Ile Ser Ala Gln Ala Ile Val
 75 80 85

Gln Gly Ile Ser Asn Pro Ser Gly Asp Leu Ser Ser Gly Ala Gly Leu
 90 95 100

30 Gly Glu Pro Lys Phe Asn Val Asp Glu Thr Ala Tyr Thr Gly Ser Trp
 105 110 115 120

Gly Arg Pro Gln Arg Asp Gly Pro Ala Leu Arg Ala Thr Ala Met Ile
 125 130 135

35 Gly Phe Gly Gln Trp Leu Leu Asp Asn Gly Tyr Thr Ser Thr Ala Thr
 140 145 150

40 Asp Ile Val Trp Pro Leu Val Arg Asn Asp Leu Ser Tyr Val Ala Gln
 155 160 165

Tyr Trp Asn Gln Thr Gly Tyr Asp Leu Trp Glu Glu Val Asn Gly Ser
 170 175 180

45 Ser Phe Phe Thr Ile Ala Val Gln His Arg Ala Leu Val Glu Gly Ser
 185 190 195 200

Ala Phe Ala Thr Ala Val Gly Ser Ser Cys Ser Trp Cys Asp Ser Gln
 205 210 215

50 Ala Pro Glu Ile Leu Cys Tyr Leu Gln Ser Phe Trp Thr Gly Ser Phe
 220 225 230

55 Ile Leu Ala Asn Phe Asp Ser Ser Arg Ser Gly Lys Asp Ala Asn Thr
 235 240 245

Leu Leu Gly Ser Ile His Thr Phe Asp Pro Glu Ala Ala Cys Asp Asp
 250 255 260

60 Ser Thr Phe Gln Pro Cys Ser Pro Arg Ala Leu Ala Asn His Lys Glu
 265 270 275 280

Val Val Asp Ser Phe Arg Ser Ile Tyr Thr Leu Asn Asp Gly Leu Ser
 285 290 295

65 Asp Ser Glu Ala Val Ala Val Gly Arg Tyr Pro Glu Asp Thr Tyr Tyr
 300 305 310

Asn Gly Asn Pro Trp Phe Leu Cys Thr Leu Ala Ala Ala Glu Gln Leu
 315 320 325
 Tyr Asp Ala Leu Tyr Gln Trp Asp Lys Gln Gly Ser Leu Glu Val Thr
 5 330 335 340
 Asp Val Ser Leu Asp Phe Phe Lys Ala Leu Tyr Ser Asp Ala Ala Thr
 345 350 355 360
 Gly Thr Tyr Ser Ser Ser Ser Ser Thr Tyr Ser Ser Ile Val Asp Ala
 10 365 370 375
 Val Lys Thr Phe Ala Asp Gly Phe Val Ser Ile Val Glu Thr His Ala
 380 385 390
 15 Ala Ser Asn Gly Ser Met Ser Glu Gln Tyr Asp Lys Ser Asp Gly Glu
 395 400 405
 Gln Leu Ser Ala Arg Asp Leu Thr Trp Ser Tyr Ala Ala Leu Leu Thr
 20 410 415 420
 Ala Asn Asn Arg Arg Asn Ser Val Val Pro Ala Ser Trp Gly Glu Thr
 425 430 435 440
 25 Ser Ala Ser Ser Val Pro Gly Thr Cys Ala Ala Thr Ser Ala Ile Gly
 445 450 455
 Thr Tyr Ser Ser Val Thr Val Thr Ser Trp Pro Ser Ile Val Ala Thr
 30 460 465 470
 Gly Gly Thr Thr Thr Thr Ala Thr Pro Thr Gly Ser Gly Ser Val Thr
 475 480 485
 35 Ser Thr Ser Lys Thr Thr Ala Thr Ala Ser Lys Thr Ser Thr Thr Thr
 490 495 500
 Arg Ser Gly Met Ser Leu
 505 510

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(ix) FEATURE:

(A) NAME/KEY: misc-feature:

(B) OTHER INFORMATION: /desc = "Primer 102434)"

(ix) FEATURE:

(A) NAME/KEY: misc-feature

(B) LOCATION: 3,6,9,12,15

(D): OTHER INFORMATION: /Note N= A,G,C or T
 R= G or A
 Y= C or T
 H= A, C or T

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

40

GTNTTAAAYA AYATHGG

17

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Primer 102435)"
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature
 (B) LOCATION: 3,6,9,12,15
 (D): OTHER INFORMATION: /Note N= A,G,C or T
 Y= C or T
 H= A, C or T
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GTNCTNAAYA AYATHGG

17

- (2) INFORMATION FOR SEQ ID NO:12:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: other nucleic acid
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Primer 117360)"
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature
 (B) LOCATION: 3,6,9,12,15
 (D): OTHER INFORMATION: /Note N= A,G,C or T
 R= G or A
 Y= C or T
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

5 CTRGANACCC TYCTYCA

17

- (2) INFORMATION FOR SEQ ID NO:13:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: other nucleic acid
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Primer 117361)"
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature
 (B) LOCATION: 3,6,12,15
 (D): OTHER INFORMATION: /Note R= G or A
 Y= C or T
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CTRAAYACCC TYCTYCA

17

10

- (2) INFORMATION FOR SEQ ID NO:14:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: other nucleic acid
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Primer 127420)"
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature
 (B) LOCATION: 6,9,12,15
 (D): OTHER INFORMATION: /Note N= A,G,C or T

R= G or A
Y= C or T

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
ACCCTYCTRC TRGGNTT

17

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(ix) FEATURE:

(A) NAME/KEY: misc-feature:

(B) OTHER INFORMATION: /desc = "Primer 123036"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
GTGAGCCCAA GTTCAATGTG

20

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(ix) FEATURE:

(A) NAME/KEY: misc-feature:

(B) OTHER INFORMATION: /desc = "Primer 1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
AGAAATCGGG TATCCTTTCA G

21

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 105 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(ix) FEATURE:

(A) NAME/KEY: misc-feature:

(B) OTHER INFORMATION: /desc = "Primer 2"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
GCTCCTCATG GTGGATCCCC AGTTGTGTAT ATAGAGGATT
5 GAGGAAGGAA GAGAAGTGTG GATAGAGGTA AATTGAGTTG
GAAACTCCA AGCATGGCATC CTTGC

105

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(ix) FEATURE:

(A) NAME/KEY: misc-feature:

(B) OTHER INFORMATION: /desc = "Primer 139746"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
GACAGATCTC CACCATGGCG TCCCTCGTTG

30

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Primer 3"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
GACCTCGAGT CACTGCCAAC TATCGTC 27

(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 29 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Primer 4"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
CCCTCACCAG GGAATGCTG CAGTTGATG 29

(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Primer 950847"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
5 CGCCATTCTC GGCGACTT 18

(2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "primer 951216"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
CGCCGCGGTA TTCTGCAG 18

(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 50 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Tal 1"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
CAATATAAAC GACGGTACCC GGGAGATCTC CACCATGGCG TCCCTCGTTG 50

(2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 44 base pairs
 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: other nucleic acid
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Tal 4"
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
 CTAATTACAT CATGCGGCC TCTAGATCAC TGCCAATAT CGTC

44

(2) INFORMATION FOR SEQ ID NO:25:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: other nucleic acid
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Tal 5"
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
 AATTGGGTC GTCCTGCTC G

21

(2) INFORMATION FOR SEQ ID NO:26:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 40 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: other nucleic acid
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Tal 6"
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
 5 CGAGCAGGAG CGACCAAAT TATTCTACT CCTGGACACG

40

(2) INFORMATION FOR SEQ ID NO:27:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: other nucleic acid
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Tal 7"
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
 GATGAGATAG TTCGCATA CG

22

(2) INFORMATION FOR SEQ ID NO:28:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 43 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: other nucleic acid
 (ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Tal 8"
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
 CGTATGCGAA CTATCTCATC GACAACGGCG AGGCTTCGAC TGC

43

(2) INFORMATION FOR SEQ ID NO:29:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Tal 9"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
CGAAGGTGGA TGAGTTCCAG 29

(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Tal 10"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
CTGGAACTCA TCCACCTTCG ACCTCTGGGA AGAAGTAGAA GG 42

(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Tal 11)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
5 GACAATACTC AGATATCCAT C 21

(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 43 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(ix) FEATURE:
 (A) NAME/KEY: misc-feature:
 (B) OTHER INFORMATION: /desc = "Tal 12"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
GATGGATATC TGAGTATTGT CGAGAAATAT ACTCCCTCAG ACG 43

(2) INFORMATION FOR SEQ ID NO: 33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2748 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "cDNA"
(vi) ORIGINAL SOURCE:
(B) STRAIN: *Talaromyces emersonii*
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

acgagatgtg	tatatactgt	gaaccaaact	agatgatgtc	agttatgctg	gtctgagaac	60
tcatagaagc	ccttgaaaat	accccaagct	agcactccaa	ccctaactct	gttgctctac	120
tagatcaaga	cgagtactct	gattgagctg	caggcttgga	atatatgatt	agcagaaaaa	180
gggttaaaac	ttgtatgaca	atcagtttgt	cagtactccg	tagtgatgcc	atgtctatag	240
agtcgacact	aaggcagcat	gtgaatgagt	cggaaatgac	aggaagcaga	ttccttaaca	300
gtcatgttct	ccgtgcctgc	atccccacgt	cacctgcaaa	gatgcgacgc	tactccacac	360
cggcgccttg	atgtctgctg	ttcctggcct	agtggagccc	catgcgctgc	tagctcgtgg	420
tcttcgaata	aatcagaata	aaaaacggag	taattaattg	cgcccgaac	aaactaagca	480
atgtaactca	atgccaagct	tccgctgatg	ctcttgacat	ctccgtagtg	gcttctttcg	540
taatttcaga	cgtatatata	gtagtaatgc	ccagcaggcc	gggataatga	tggggatttc	600
tgaactctca	gcttccgtac	gctgaacagt	ttgcttgctg	tgtcaaccat	ggcgtccctc	660
gttgctggcg	ctctctgcat	cctgggcctg	acgcctgctg	catttgacgc	agcgcctggt	720
gcagcgcgag	ccaccgggtc	cctggactcc	ttctctgcaa	ccgaaactcc	aattgccctc	780
caaggcgtgc	tgaacaacat	cgggcccact	ggtgctgatg	tggcaggagc	aagcgccggc	840
attgtggttg	ccagtccgag	caggagcgac	ccaaattgta	ggttctttcc	caccagaaat	900
tacttattta	aatcagccct	ctgacagggt	gaagatttct	actcctggac	acgtgacgca	960
gcgctcacgg	ccaaatacct	cgtcgacgcc	ttcatcgctg	gcaacaagga	cctagagcag	1020
accatccagc	agtacatcag	cgcgcaggcg	aagggtgcaa	ctatctccaa	tccgtccgga	1080
gatttatcca	ccggtggcct	aggtgagccc	aagttcaatg	tgaatgagac	ggcttttacc	1140
gggcccctgg	gtcgtccaca	gagggacgga	ccagcgttga	gagcgacggc	cctcattgcg	1200
tatgcgaact	atctcatcgt	aagcttctgc	tcgctgccct	tctctctgct	cgtatgctaa	1260
gtagtcctgt	caggacaacg	gcgaggcttc	gactgccgat	gagatcatct	ggccgattgt	1320
ccagaatgat	ctgtcctaca	tcaccaata	ctggaactca	tccaccttcg	gtaggcaaat	1380
gaatattccc	gacacagcgt	ggtactaatt	tgattcagac	ctctgggaag	aagtagaagg	1440
atcctcattc	ttcacaaccg	ccgtgcaaca	ccgcgccttg	gtcgaaggca	atgcactggc	1500
aacaaggctg	aaccacacgt	gtcceaactg	cgtctctcag	gcccctcagg	tcctgtgttt	1560
cctgcagtca	tactggaccg	gacgtatgt	tctggccaac	tttgggtggc	gcggtcgttc	1620
cggcaaggac	gtgaattcga	ttctgggcag	catccacacc	tttgatcccg	ccggaggctg	1680
tgacgactcg	accttcacgc	cgtgttcggc	ccgtgccttg	gcaaatcaca	aggtggtcac	1740
cgactcgttc	cggagtatct	atgcgatcaa	ctcaggcatc	gcagagggat	ctgccgtggc	1800
agtcggccgc	taccctgagg	atgtctacca	gggcgggaac	ccctggtacc	tggccacagc	1860
agcggctgca	gagcagcttt	acgacgccat	ctaccagtgg	aagaagatcg	gctcgataag	1920
tatcacggac	gttagtctgc	cattttttcca	ggatatctac	ccttctgccg	cgggtgggcac	1980
ctataactct	ggctccacga	ctttcaacga	catcatctcg	gccgtccaga	cgtatggtga	2040
tggatatctg	agtattgtcg	tacgtttttg	cttagattct	cagggtgtaa	gaaaaaaatg	2100
gaactaactc	agttctagga	gaaatatact	ccctcagacg	gctctcttac	cgaacaattc	2160
tcccgtacag	acggcactcc	gctttctgcc	tctgccctga	cttgggtcgta	cgcttctctc	2220
ctaaccgctt	cggcccgcag	acagtcctgc	gtccctgctt	cctggggcgga	aagctccgca	2280
agcagcgtcc	ctgccgtctg	ctctgccacc	tctgccacgg	gcccatacag	cacggctacc	2340
aacaccgtct	ggccaagctc	tggctctggc	agctcaacaa	ccaccagtag	cgccccatgc	2400
accactccta	cctctgtggc	tgtgaccttc	gacgaaatcg	tcagcaccag	ttacggggag	2460
acaatctacc	tggccggctc	gatccccgag	ctgggcaact	ggtccacggc	cagcgcgatc	2520
cccctccgcg	cggatgctta	caccaacagc	aaccgcgtct	ggtacgtgac	cgtcaatctg	2580
ccccctggca	ccagcttcga	gtacaagtgc	ttcaagaacc	agacggacgg	gaccatcgtc	2640
tgggaagacg	acccgaaccg	gtcgtacacg	gtcccagcgt	actgtgggca	gactaccgcc	2700
attcttgacg	atagttggca	gtgagataac	atccaccctt	ctgtttta		2748

60 (2) INFORMATION FOR SEQ ID NO: 34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 618 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(vi) ORIGINAL SOURCE:
(B) STRAIN: *Talaromyces emersonii*
65

(a) FEATURE:

(b) NAME/KEY: SIGNAL

(c) LOCATION: (1)...(27)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

5	Met	Ala	Ser	Leu	Val	Ala	Gly	Ala	Leu	Cys	Ile	Leu	Gly	Leu	Thr	Pro
	1			5					10					15		
	Ala	Ala	Phe	Ala	Arg	Ala	Pro	Val	Ala	Ala	Arg	Ala	Thr	Gly	Ser	Leu
			20					25					30			
	Asp	Ser	Phe	Leu	Ala	Thr	Glu	Thr	Pro	Ile	Ala	Leu	Gln	Gly	Val	Leu
10		35					40					45				
	Asn	Asn	Ile	Gly	Pro	Asn	Gly	Ala	Asp	Val	Ala	Gly	Ala	Ser	Ala	Gly
	50					55				60						
	Ile	Val	Val	Ala	Ser	Pro	Ser	Arg	Ser	Asp	Pro	Asn	Tyr	Phe	Tyr	Ser
	65				70				75						80	
15	Trp	Thr	Arg	Asp	Ala	Ala	Leu	Thr	Ala	Lys	Tyr	Leu	Val	Asp	Ala	Phe
			85					90						95		
	Ile	Ala	Gly	Asn	Lys	Asp	Leu	Glu	Gln	Thr	Ile	Gln	Gln	Tyr	Ile	Ser
		100					105						110			
	Ala	Gln	Ala	Lys	Val	Gln	Thr	Ile	Ser	Asn	Pro	Ser	Gly	Asp	Leu	Ser
20		115					120						125			
	Thr	Gly	Gly	Leu	Gly	Glu	Pro	Lys	Phe	Asn	Val	Asn	Glu	Thr	Ala	Phe
	130					135						140				
	Thr	Gly	Pro	Trp	Gly	Arg	Pro	Gln	Arg	Asp	Gly	Pro	Ala	Leu	Arg	Ala
	145				150				155						160	
25	Thr	Ala	Leu	Ile	Ala	Tyr	Ala	Asn	Tyr	Leu	Ile	Asp	Asn	Gly	Glu	Ala
			165				170						175			
	Ser	Thr	Ala	Asp	Glu	Ile	Ile	Trp	Pro	Ile	Val	Gln	Asn	Asp	Leu	Ser
		180					185						190			
	Tyr	Ile	Thr	Gln	Tyr	Trp	Asn	Ser	Thr	Phe	Asp	Leu	Trp	Glu	Glu	
30		195				200						205				
	Val	Glu	Gly	Ser	Ser	Phe	Phe	Thr	Thr	Ala	Val	Gln	His	Arg	Ala	Leu
	210					215						220				
	Val	Glu	Gly	Asn	Ala	Leu	Ala	Thr	Arg	Leu	Asn	His	Thr	Cys	Ser	Asn
	225				230				235						240	
35	Cys	Val	Ser	Gln	Ala	Pro	Gln	Val	Leu	Cys	Phe	Leu	Gln	Ser	Tyr	Trp
			245				250							255		
	Thr	Gly	Ser	Tyr	Val	Leu	Ala	Asn	Phe	Gly	Gly	Ser	Gly	Arg	Ser	Gly
		260					265						270			
	Lys	Asp	Val	Asn	Ser	Ile	Leu	Gly	Ser	Ile	His	Thr	Phe	Asp	Pro	Ala
40		275					280						285			
	Gly	Gly	Cys	Asp	Asp	Ser	Thr	Phe	Gln	Pro	Cys	Ser	Ala	Arg	Ala	Leu
	290					295						300				
	Ala	Asn	His	Lys	Val	Val	Thr	Asp	Ser	Phe	Arg	Ser	Ile	Tyr	Ala	Ile
	305				310				315						320	
45	Asn	Ser	Gly	Ile	Ala	Glu	Gly	Ser	Ala	Val	Ala	Val	Gly	Arg	Tyr	Pro
			325				330							335		
	Glu	Asp	Val	Tyr	Gln	Gly	Gly	Asn	Pro	Trp	Tyr	Leu	Ala	Thr	Ala	Ala
		340					345						350			
	Ala	Ala	Glu	Gln	Leu	Tyr	Asp	Ala	Ile	Tyr	Gln	Trp	Lys	Lys	Ile	Gly
50		355					360						365			
	Ser	Ile	Ser	Ile	Thr	Asp	Val	Ser	Leu	Pro	Phe	Phe	Gln	Asp	Ile	Tyr
	370					375						380				
	Pro	Ser	Ala	Ala	Val	Gly	Thr	Tyr	Asn	Ser	Gly	Ser	Thr	Thr	Phe	Asn
	385				390				395						400	
55	Asp	Ile	Ile	Ser	Ala	Val	Gln	Thr	Tyr	Gly	Asp	Gly	Tyr	Leu	Ser	Ile
			405				410							415		
	Val	Glu	Lys	Tyr	Thr	Pro	Ser	Asp	Gly	Ser	Leu	Thr	Glu	Gln	Phe	Ser
		420					425						430			
	Arg	Thr	Asp	Gly	Thr	Pro	Leu	Ser	Ala	Ser	Ala	Leu	Thr	Trp	Ser	Tyr
60		435					440						445			
	Ala	Ser	Leu	Leu	Thr	Ala	Ser	Ala	Arg	Arg	Gln	Ser	Val	Val	Pro	Ala
	450					455						460				
	Ser	Trp	Gly	Glu	Ser	Ser	Ala	Ser	Ser	Val	Pro	Ala	Val	Cys	Ser	Ala
	465				470				475					480		
65	Thr	Ser	Ala	Thr	Gly	Pro	Tyr	Ser	Thr	Ala	Thr	Asn	Thr	Val	Trp	Pro
			485				490						495			
	Ser	Ser	Gly	Ser	Gly	Ser	Ser	Thr	Thr	Thr	Ser	Ser	Ala	Pro	Cys	Thr
			500				505						510			

[illegible]

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00520

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 9/34, C12N 1/14 // C12P 19/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CA, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0255124 A2 (HITACHI, LTD.), 3 February 1988 (03.02.88), claim 4 --	1-28
X	US 4247637 A (MASAKI TAMURA ET AL), 27 January 1981 (27.01.81), claim 5 --	1-28
X	EP 0135138 A2 (CPC INTERNATIONAL INC.), 27 March 1985 (27.03.85), claim 1 --	1-28
A	Patent Abstracts of Japan, Vol 11, No 184, C-427 abstract of JP 62-6678 A (TAX ADM AGENCY), 13 January 1987 (13.01.87) --	1-28



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 March 1999

Date of mailing of the international search report

20 -03- 1999

Name and mailing address of the ISA/

Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Yvonne Siösteen
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00520

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4587215 A (JODY K. HIRSH), 6 May 1986 (06.05.86), abstract --	1-28
A	WO 8601831 A1 (MICHIGAN BIOTECHNOLOGY INSTITUTE), 27 March 1986 (27.03.86), claim 3 --	1-28
A	Dialog Information Services, File 351, DERWENT WPI, Dialog accession no. 007454391, WPI accession no. 88-088325/198813, Hitachi Ltd: "Aerobic Clostridium sp. G-0005 bacterium - which produces thermo- resistant and acid-resistant glucoamylase", JP 63039577 A 19880220, week 198813 B --	1-28
A	EMBL, Databas/Genbank/DDBJ, Accession no. D01035, Hata Y et al: "The glucoamylase cDNA from Aspergillus oryzae: its cloning, nucleotide", AOGLA 09-OCT-1993, & Agric. Biol. Chem. 55:941-949 (1991) SEQ ID No 7, 62% homology --	1-28
X	EMBL, Databas/Genbank/DBJ, Accession no. P40212, Cetus Corp.: "Sequence encoded by A. awamori glucoamylase genomic region", Geneseq P40212, 09-JAN-1992, & W08402921-A, SEQ ID No 2, 90% homology --	8-9
X	EMBL, Databas/Genbank/DDBJ, Accession no. E03645, Hata Y. et al: "Novel gene, vector, trans- formant using the same and use of the transformant", Empatent: E03645, 08-OCT-1997, & Patent number JP 1992148683-A/1, 21-MAY-1992 SEQ ID No 3, 86% homology --	8-9

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 98/00520

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EMBL,Databas/Genbank/DDBJ, Accession no. P36914, Hata Y. et al: "Glucoamylase precursor (EC3.2.1.3) (Glucan 1,4-Alpha-Gucosidase)(1,4-Alpha-D-Glucan glucohydrolase), Swissprot. AMYG ASPOR, 01-JUN-1994, & Agric. Biol. Chem. 55:941-949 (1991), SEQ ID No 3, 85,7% homology</p> <p>--</p>	8,9
X	<p>EMBL,Databas,Genbank/DDBJ), Accession no. Q04731, Jozo Shigen Kenkyus: "cDNA sequence from mRNA of glucoamylase gene", Geneseq Q04731 12-OCT-1990, & J02119779-A, SEQ ID No 4 83% homology</p> <p>--</p>	8-9
X	<p>EMBL,Databas/Genbank/DDBJ, Accession no. L15383, Ventura L. et al: "Molecular cloning and transcriptional analysis of the Aspergillus", ATGLUAMY, 15-MAR-1994, & Appl.Environ.Microbiol. 61:399-402(1995) SEQ ID No 5, 88% homology</p> <p>-- -----</p>	8-9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK98/00520

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 3 and part of claims 4-7
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claim 3 and part of claims 4-7 are searched incompletely because they are not clear and concise. (Article 6).

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The claims are formulated in such a way that they could relate to two individual enzymes each of which represents a separate invention:

- 1) a glycoamylase having a half-life of at least 100 minat 70°C according to claim 1 and related claims.
- 2) a glycoamylase having a specific activity towards maltose at 60°C according to claim 3 and related claims.

However the description indicates that the claims relate to a single enzyme., namely a thermostable glycoamylase having a half-life according to claim 1 and a specific activity of claim 3.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

02/03/99

International application No.
PCT/DK 98/00520

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0255124 A2	03/02/88	JP 1725113 C JP 4007672 B JP 63036778 A JP 1745780 C JP 4028356 B JP 63042695 A	19/01/93 12/02/92 17/02/88 25/03/93 14/05/92 23/02/88
US 4247637 A	27/01/81	AR 221619 A AU 528159 B AU 4949079 A BE 878466 A CA 1128885 A DE 2935315 A DK 146631 B,C DK 365179 A FR 2434867 A,B GB 2029835 A,B IN 151247 A IN 154830 A JP 1389970 C JP 55034046 A JP 61055948 B NL 7906265 A US RE32153 E	27/02/81 14/04/83 06/03/80 17/12/79 03/08/82 13/03/80 21/11/83 02/03/80 28/03/80 26/03/80 12/03/83 15/12/84 23/07/87 10/03/80 29/11/86 04/03/80 20/05/86
EP 0135138 A2	27/03/85	AU 575844 B AU 3170884 A CA 1221326 A DK 393284 A FI 842916 A GB 2145094 A,B IN 160378 A JP 60054680 A US 4536477 A	11/08/88 21/02/85 05/05/87 18/02/85 18/02/85 20/03/85 11/07/87 29/03/85 20/08/85
US 4587215 A	06/05/86	NONE	
WO 8601831 A1	27/03/86	EP 0195068 A US 4628031 A US 4737459 A	24/09/86 09/12/86 12/04/88

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.